<!DOCTYPE html>

<html> 

<head> <!-- /main page header -->
  <meta charset="UTF-8">
   <meta name="format-detection" >
   <meta name="viewport" content="user-scalable=no, initial-scale=5, minimum-scale=1, maximum-scale=5">
   <title>BD-MIMS</title>
   <link rel="stylesheet" href="css/main.css">
   <link rel="stylesheet" href="css/themes/default/jquery.mobile-1.3.1.min.css">
   <script src="js/jquery.js"></script>
   <script src="js/jqm.js"></script>
   <script scr="js/cordova.js"type="text/javascript"></script>
   <script>
    function init() {
      document.addEventListener("deviceready", onDeviceReady, false);
    }

    function onDeviceReady() {
      alert('Damn Niagga, its playtime!');
    }
  </script>
   
</head> <!-- /main page header -->


<body onload="init()"> 

<div data-role="page" id="" data-theme="a"> <!-- /first page -->


    <div data-role="header"> <!-- /this is header -->
      <h1>Cardiovascular System</h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>

    </div> <!-- /this is header -->


   <div data-role="content" data-theme="a">  <!-- /content div -->
      <ul data-role="listview" data-inset="true" data-theme="b">        
         
            
                   
  <li><a href="#Combined antihypertensive preparations">
      Combined Drugs (Anti Hypertensive drugs)</a>
  </li>                                           
                

  <li>  Drugs used in angina  & ischaemic heart diseases
           <ul> 
               <li><a href="#Nitrates: Coronary vasodilators">
                Nitrates: Coronary vasodilators</a>
                <li><a href="#Calcium-channel blockers">
                Calcium-channel blockers</a>
                <li><a href="#Potassium-channel activators">
                Potassium-channel activators</a>
                <li><a href="#Misc. Antianginal & anti-ischaemic drugs">
                Misc. Antianginal & anti-ischaemic drugs</a>
              </li>                         
          </ul>    
    </li>



    <li>  Peripheral & cerebral vasodilator drugs
       <ul> 
           <li><a href="#Cerebral vasodilator & Neurosensory oxygenator drugs">
            Cerebral vasodilator & Neurosensory oxygenator drugs</a>
          </li>  
          <li><a href="#Peripheral vasodilator drugs">
            Peripheral vasodilator drugs</a>
          </li>  
          <li><a href="#Drugs for Muscular energy metabolism">
            Drugs for Muscular energy metabolism</a>
          </li>                                
      </ul>    
   </li>


   <li>  Sympathomimetics
        <ul> 
           <li><a href="#Inotropic sympathomimetics">
            Inotropic sympathomimetics</a>
          </li> 
          <li><a href="#Vasoconstrictor sympathomimetics">
            Vasoconstrictor sympathomimetics</a>
          </li>  
                                   
      </ul>    
   </li>



   <li> Anticoagulants & Protamine
        <ul> 
           <li><a href="#Parenteral anticoagulants">
            Parenteral anticoagulants</a>
          </li>
          <li><a href="#Oral anticoagulants">
            Oral anticoagulants</a>
          </li>                                                  
      </ul>    
   </li>
   


   <li>Antiplatelet drugs
        <ul> 
           <li><a href="#Aspirin">
            Aspirin</a>
          </li>
          <li><a href="#CLOPIDOGREL">
            Clopidogrel</a>
          </li> 
          <li><a href="#CLOPIDOGREL + ASPIRIN">
            CLOPIDOGREL + ASPIRIN</a>
          </li>                                       
      </ul>    
   </li>

        
  <li><a href="#FIBRINOLYTIC DRUGS">Fibrinolytic drugs</a></li>

  <li><a href="#Antifibrinolytic & haemostatic drugs">Antifibrinolytic & haemostatic drugs</a></li>    
                                      
    

  <li> Lipid-lowering drugs
        <ul> 
           <li><a href="#Ezetimibe">Ezetimibe</a></li>
           <li><a href="#Fibrates">Fibrates</a></li>
           <li><a href="#Gemfibrozil">Gemfibrozil</a></li>
           <li><a href="#Statins">Statins</a></li>          
           <li><a href="#Fluvastatin">Fluvastatin</a></li>
           <li><a href="#Lovastatin">Lovastatin</a></li>
           <li><a href="#Rosuvastatin">Rosuvastatin</a></li>
           <li><a href="#Simvastatin">Simvastatin</a></li>                                             
      </ul>    
  </li>



  <li><a href="#Nicotinic acid group">Nicotinic acid group</a></li>
              

</div> <!-- content div -->

   <div data-role="footer"data-position="fixed"> <!-- /first footer -->
      <h4></h4>
   </div><!-- /first footer -->
  </div> <!-- /first page -->
 
  <!-- /page snippet -->




<!-- /................page............................ -->



<div data-role="page" id="Combined antihypertensive preparations" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Combined antihypertensive preparations   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

     <ul data-role="listview" data-inset="true" data-theme="b">        
     
       

        <li><a href="#INDAPAMIDE + PERINDOPRIL">INDAPAMIDE + PERINDOPRIL</a></li>

        <li><a href="#CANDESARTAN+HYDROCHLOROTHIAZIDE">CANDESARTAN + HYDROCHLOROTHIAZIDE</a></li>

        <li><a href="#IRBESARTAN + HYDROCHLOROTHIAZIDE">IRBESARTAN + HYDROCHLOROTHIAZIDE</a></li>

        <li><a href="#LOSARTAN + HYDROCHLOROTHIAZIDE">LOSARTAN + HYDROCHLOROTHIAZIDE</a></li> 

        <li><a href="#TELMISARTAN HYDROCHLOROTHIAZIDE">TELMISARTAN HYDROCHLOROTHIAZIDE </a></li> 

        <li><a href="#VALSARTAN">VALSARTAN + HYDROCHLOROTHIAZIDE</a></li> 
</ul>

    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="INDAPAMIDE + PERINDOPRIL" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> INDAPAMIDE + PERINDOPRIL   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

   <div data-role="collapsible-set" data-theme="b">

            <div data-role="collapsible"> <!-- collapsible -->
              <h3> INDAPAMIDE + PERINDOPRIL: Tablet  </h3>
              <p> This is a fixed combination of indapamide and perindopril; preparations are available in two presentations, viz: i. tablet containing indapamide 0.625mg and perindopril erbumine 2mg, and ii. tablet containing indapamide 1.25mg and perindopril erbumine 4mg.<br><br>
In this combination perindopril is an ACE inhibitor and indapamide is a thiazide-like diuretic, both of these lead to additive synergy of the antihypertensive effects of the product. Mode of action: The pharmacological actions of these two components are derived from those of each of the components taken separately. In addition to those due to the additive synergistic action of the two constituents, when combined, it shows beneficial effets on vascular endothelium, arteriolocapillary microcirculation, and the target organs of hypertension.
Ind: Essential hypertension.<br><br>

<strong>C/I:</strong> Absolute: Known allergy to perindopril erbumine, indapamide, or sulfonamides; history of Quincke's edema linked to previous ACE inhibitor therapy; severe renal failure; serious liver disorder; hypokalemia; pregnancy and lactation. Relative: Combination therapy with lithium, potassium salts, potassium-sparing diuretics & certain medicines which can cause heart rhythm disorders.<br><br>

<strong>S/E:</strong> Asthenia, dizziness, headache, mood swings and/or sleep disturbances, cramps, hypotension, allergic reactions, skin rashes, gastrointestinal disorders, dry cough, dry mouth, risk of dehydrat- ion in the elderly & in patients suffering from heart failure; changes in blood test results may occur. Precautions: Disorders of electrolyte balance, diabetes, gout, hypotension, or strict sodium-free diets, heart or renal failure, atherosclerosis, renal artery stenosis, elderly.<br><br>

<strong>Pregnancy & lactation:</strong> This combination is absolutely contraindicated in pregnancy & lactation. <br><br>

<strong>Dosage & admin:</strong> One tablet daily (strength as advised by the physician), preferably to be taken in the morning and before a meal.<br> 
Elderly patients: Normal dosage.<br>
Renal failure: Creatinine clearance (CrCl) >30ml/min: No dosage <br>modification. CrCl less than 30ml/min: treatment contraindicated.<br><br>

<strong>Drug inter:</strong> Not recommended: combinations with lithium, potassium-sparing diuretics, potassium (salts), antiarrhythmic drugs which cause torsade de pointes, anesthetic drugs, cytostatic or immunosuppressive agents.   </p>
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>INDAPRIL 2 Tab. Incepta</h3>
                <p>Indapamide 0.625mg and perindopril erbumine 2mg/tablet
            IRBESARTAN + HYDROCHLOROTHIAZIDE 81
            30's pack: 210.00 MRP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>INDAPRIL 4 Tab. Incepta</h3>
                <p>Indapamide 1.25mg and perindopril erbumine 4mg/tablet
            20's pack: 240.00 MRP</p> 
            </div><!-- collapsible -->  

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>INDURIC Plus Tab. Beximco</h3>
                <p>Indapamide BP 1.25mg and perindopril erbumine INN 4mg/tablet
            30's pack: 210.00 IP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>INOPIL 2 Plus Tab. Delta</h3>
                <p>Indapamide 0.625mg and perindopril erbumine 2mg/tablet
            20's pack: 120.00 MRP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>INOPIL Plus Tab. Delta Indapamide</h3>
                <p>BP 1.25mg and perindopril erbumine INN 4mg/tablet 10's pack: 120.00 MRP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>MIDOPRIL 2 Tab. General</h3>
                <p>Indapamide 0.625mg and perindopril erbumine 2mg/tablet
            30's pack: 210.00 MRP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>MIDOPRIL 4 Tab. General</h3>
                <p>Indapamide 1.25mg and perindopril erbumine 4mg/tablet
            20's pack: 240.00 MRP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>PENDORIL Plus 2 Tab. Renata</h3>
                <p>Indapamide 0.625mg and perindopril erbumine 2mg/tablet
            10's pack: 80.00 MRP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>PENDORIL Plus 4 Tab. Renata</h3>
                <p>Indapamide 1.25mg and perindopril erbumine 4mg/tablet 10's pack: 130.00 MRP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>PERINDAL 2+ Tab. Opsonin </h3>
                <p>Indapamide 0.625mg and perindopril erbumine 2mg/tablet
            30's pack: 210.00 MRP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>PERINDAL 4+ Tab. Opsonin</h3>
                <p>Indapamide 1.25mg and perindopril erbumine 4mg/tablet
            20's pack: 360.00 MRP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>REPRES Plus 2 Tab. Square</h3>
                <p>Indapamide 0.625mg and perindopril erbumine 2mg/tablet 30's pack: 210.00 MRP</p>   
            </div><!-- collapsible -->

            <div data-role="collapsible"> <!-- collapsible -->
                <h3>REPRES Plus 4 Tab. Square</h3>
                <p>Indapamide 1.25mg and perindopril erbumine 4mg/tablet
            20's pack: 240.00 MRP</p>   
            </div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->




<!-- /................page............................ -->



<div data-role="page" id="CANDESARTAN+HYDROCHLOROTHIAZIDE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  CANDESARTAN+HYDROCHLOROTHIAZIDE  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

          <div data-role="collapsible"> <!-- collapsible -->
            <h3> CANDESARTAN + HYDROCHLOROTHIAZIDE: Tablet  </h3>
            <p>  Combination preparation of candesartan and hydrochlorothiazide is available as candesartan cilexetil INN 8mg & hydrochlorothiazide BP 12.5mg/tablet.<br><br>

<strong>Mode of action:</strong> Angiotensin II is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Candesartan blocks the vasoconstrictor and aldosterone- secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g vascular smooth muscle, adrenal gland). Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics. Ind: These combined preparations are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy of hypertension, except when the hyperte- nsion is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients. <br><br>

<strong>C/I:</strong> This combination is contraindicated in patients- i. who are hypersensitive to any component of this product; ii. hydrochlorothiazide is particularly contraindicated in patients with anuria or hypersensitivity to other sulfonamide group of drugs; iii. pregnancy & lactation.<br><br>

<strong>S/E:</strong> Adverse effects are generally mild and transient in nature. The overall incidence of adverse events reported with this combination occurring in greater than 2% of patients are- respiratory tract infection (3.6%), back pain (3.3%), influenza-like symptoms (2.5%), dizziness (2.9%), and headache (2.9%).<br><br>

<strong>Precautions:</strong> In clinical trials of various doses of candesartan cilexetil and hydrochlorothiazide, the incidence of hypertensive patients who developed hypokalemia (serum potassium 3.5mEq/L) was 2.5% versus 2.1% for placebo; the incidence of hyperkalemia (serum potassium >5.7mEq/L) was 0.4% versus 1.0% for placebo. No patient receiving this combination 16-12.5mg had to discontinue the drug due to increases or decreases in serum potassium. Overall, the combination of candesartan cilexetil and hydrochlorothiazide had no clinically significant effect on serum potassium. Pregnancy & lactation: When pregnancy is detected, this drug should be discontinued as soon as possible. It should not be used in lactation also. Dosage & admin: Initially 4mg (2mg in hepatic and renal impairment) once daily adjusted according to response; usual maintenance dose is 8mg once daily; maximum 32mg once daily. Doses larger than 32mg do not appear to have a greater blood pressure lowering effect. Hydorchlorothiazide is effective in doses of 12.5 to 50mg once daily.<br><br>

<strong>Drug inter:</strong> See above under the text of 'candesartan cilexetil' & 'hydrochlorothiazide' separately.  </p>
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>GIRAN-H Tab. Aristopharma</h3>
              <p>Candesartan cilexetil INN 8mg & hydrochlorothiazide BP 12.5mg/tablet. 30's pack: 180.00 MRP</p>   
          </div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->




<!-- /................page............................ -->



<div data-role="page" id="IRBESARTAN + HYDROCHLOROTHIAZIDE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> IRBESARTAN + HYDROCHLOROTHIAZIDE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

<div data-role="collapsible"> <!-- collapsible -->
  <h3> IRBESARTAN + HYDROCHLOROTHIAZIDE: Tablet  </h3>
  <p> Combination preparations of irbesartan and hydrochlorothiazide are available in three fixed- dose presentations, viz: i. Irbesartan INN 150mg + Hydrochlorothiazide BP 12.5mg/tablet, ii. Irbesartan INN 300mg + Hydrochlorothiazide BP 12.5mg/tablet, and iii. Irbesartan INN 300mg + Hydrochlorothiazide BP 25mg/tablet. Mode of action: See above under the text of 'Candesartan + Hydrochlorothiazide' preparation. 

<strong>Ind:</strong> This combination is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.<br><br>

<strong>C/I:</strong> See above under the text of 'Candesartan + Hydrochlorothiazide' preparation.<br><br>

<strong>S/E;</strong> Precaution & warning: See above under the text of 'Candesartan + Hydrochlorothiazide' prepn.<br><br><strong></strong> 

<strong>Pregnancy & lactation:</strong> When pregnancy is detected, this drug should be discontinued as soon as possible. It should not he used in lactation also. <br><br>

<strong>Dosage & admin:</strong> A patient whose blood pressure is inadequately controlled by irbesartan or hydrochlorothiazide alone may be switched to this combination product once daily to minimize dose independent side effects. Recommended doses of this product, in order of increasing mean effect, are (irbesartan/ hydrochlorothiazide) 150mg/12.5mg, 300mg/ 12.5mg, and 300mg/25mg. The largest incremental effect will likely be in the transition from monotherapy to 150mg/12.5mg. It takes 2- 4 weeks for the blood pressure to stabilize after a change in the dose of this combination product. The usual dose of product is one
tablet (150mg/12.5mg) once daily. More than two tablets once daily is not recommended. The maximal antihypertensive effect is attained about 2-4 weeks after initiation of therapy.
Use in patients with renal impairment: The usual regimens of therapy with this product may be followed as long as the patient's creatinine clearance is 30ml/min.
Patients with hepatic impairment: No dosage adjustment is necessary in patients with hepatic impairment.<br><br>

<strong>Drug inter:</strong> See above under the text of 'irbesartan' and 'hydrochlorothiazide' separately.   </p>
</div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAVAZIDE-75 Tab. UniHealth/UniMed</h3>
    <p>Irbesartan INN 75mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAVAZIDE-150 Tab. UniHealth/UniMed</h3>
    <p>Irbesartan INN 150mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 360.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAVAZIDE-300 Tab. UniHealth/UniMed</h3>
    <p>Irbesartan INN 300mg & hydrochlorothiazide 12.5mg/tablet.
10's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="LOSARTAN + HYDROCHLOROTHIAZIDE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> LOSARTAN + HYDROCHLOROTHIAZIDE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>LOSARTAN + HYDROCHLOROTHIAZIDE: Tablet   </h3>
                <p> Combination preparations of losartan potassium and hydrochlorothiazide are available in two fixed strengths, viz: i. Losartan potassium INN 25mg + Hydrochlorothiazide BP 12.5mg, and ii. Losartan potassium INN 50mg + Hydrochlorothiazide BP 12.5mg.<br><br>

<strong>Mode of action:</strong> See above under the text of 'Candesartan + Hydrochlorothiazide' preparation.<br><br>

<strong>Ind:</strong> These combined preparations are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy of hypertension, except when the hyperten- sion is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients. <br><br>

<strong>C/I:</strong> This combination is contraindicated in patients who are hypersensitive to any component of this product. Hydrochlorothiazide is particularly contraindicated in patients with anuria or hypersen- sitivity to other sulfonamide group of drugs.<br><br>

<strong>S/E:</strong> Generally this combination is well tolerated. However, few side-effects including abdominal pain, swelling, back pain, dizziness, rash and cough may occur in rare cases.<br><br>

<strong>Precautions & Warnings:</strong> In patients treated with various doses of losartan and hydrochlorothiazide, there was a dose-related decrease in the hypokalemic response to hydrochlorothiazide as the dose of losartan was increased, as well as a dose-related decrease in serum uric acid with increasing doses of losartan. Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.<br>

In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. <br>

Hypotension: In patients who are intravascularly volume-depleted (e.g those treated with diuretics), symptomatic hypotension may occur after initiation of this combined therapy.<br>

Impaired hepatic functions: This combination is not recommended for patients with hepatic impairment who require titration with losartan. The lower starting dose of losartan recommended for that patients.<br>

Patients with renal impairment: In patients with more severe renal impairment this is not recommended.<br><br>

<strong>Pregnancy & lactation:</strong> When pregnancy is detected, this drug should be discontinued as soon as possible. It should not be used in lactation also.
<br><br> 

<strong>Dosage & admin:</strong> Dosing must be individualized.
The usual starting dose of losartan is 50mg once daily; 25mg is recommended for patients with intravascular volume depletion and patients with a history of hepatic impairment. Losartan can be administered once or twice daily at total daily doses of 25mg to 100mg. If the antihypertensive effect measured at trough using once-a-day dosing is inadequate, a twice- a-day regimen at the same total daily dose or an increase in dose may give a more satisfactory reporse.Hydrochlorothiazide is effective in doses of 12.5mg to 50mg once daily and can be given at doses of 12.5mg to 25mg.
To minimize dose-dependent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy. These combinations may also be administered with other antihypertensive agents if required. Paediatric use: Safety and effectiveness in paediatric patients have not been established. Drug inter: See above under the text of 'losartan potassium' & 'hydrochlorothiazide' separately. </p>
              </div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGILOCK Plus Tab. Square</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGILOCK Plus 100/12.5 Tab. Square</h3>
    <p>Losartan potassium 100mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 270.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGILOCK Plus 100/25 Tab. Square</h3>
    <p>Losartan potassium 100mg & hydrochlorothiazide 25mg/tablet.
30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANREB Plus Tab. General</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ARATEN Plus-25 Tab. UniHealth</h3>
    <p>Losartan potassium 25mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 105.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ARATEN Plus-50 Tab. UniHealth</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARDOPLUS 50 Tab. SK+F</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
20's pack: 120.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARDOPLUS 100 Tab. SK+F</h3>
    <p>Losartan potassium 100mg & hydrochlorothiazide 12.5mg/tablet.
20's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>HYPANIL Tab. Aexim</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOPOS Plus Tab. Zenith</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
50's pack: 500.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOSACOR Plus Tab. Healthcare</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 195.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOSAN-D Tab. Orion</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOSARCAR-PLUS Tab. Medimet</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOSARDIL-Plus 25 Tab. Drug Inter.</h3>
    <p>Losartan potassium 25mg & hydrochlorothiazide 12.5mg/tablet.
50's pack: 250.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOSARDIL-Plus 50 Tab. Drug Inter.</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
50's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOSART Plus Tab. Acme</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOSATAN HZ Tab. Popular</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 180.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOSIUM Plus-50 Tab. Ibn Sina</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet. 30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOSPIL Plus Tab. White Horse Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet. 50's pack: 300.00 MRP</h3>
    <p></p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>OSARTAN-HZ Tab. Aristopharma</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>OSARTIL 50 Plus Tab. Incepta</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet. 30's pack: 180.00 MRP</p> </div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>OSARTIL 100 Plus Tab. Incepta</h3>
    <p>Losartan potassium 100mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PROSAN HZ Tab. Beximco</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet.
30's pack: 180.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>REPACE H Tab. Sun Pharma</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet. 50's pack: 350.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ROSATAN-H 25 Tab. ACI</h3>
    <p>Losartan potassium 25mg & hydrochlorothiazide 12.5mg/tablet 50's pack: 120.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ROSATAN-H 50 Tab. ACI</h3>
    <p>Losartan potassium 50mg & hydrochlorothiazide 12.5mg/tablet. 50's pack: 300.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="TELMISARTAN HYDROCHLOROTHIAZIDE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> TELMISARTAN HYDROCHLOROTHIAZIDE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

          <div data-role="collapsible"> <!-- collapsible -->
            <h3> TELMISARTAN + HYDROCHLOROTHIAZIDE: Tablet </h3>
            <p> The combination preparations of telmisartan & hydrochlorothiazide are available in two fixed- dose presentations, viz: i. Telmisartan INN 40mg + Hydrochlorothiazide BP 12.5mg/tablet; ii. Telmisartan INN 80mg + Hydrochlorothiazide BP 12.5mg/tablet.<br><br>

<strong>Mode of action:</strong> See above under the text of 'Candesartan + Hydrochlorothiazide' preparation. Ind: These combined preparations are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy of hypertension.<br><br>

<strong>C/I:</strong> This combined preparation is contraindicated in patients who are hypersensitive to any component of this product; patients with anuria or hypersensitivity to other sulfonamide derived drugs. <br><br>

<strong>S/E:</strong> Most side effects are mild in intensity & transient in nature & did not require discontinuation of therapy. Common side effects are diarrhea, nausea, dizziness, cough and fatigue. Precautions: Impaired hepatic functions: As the majority, telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or hepatic insufficiency can be expected to have reduced clearance. Telmisartan should be used with caution in these patients. Impaired renal function: As a consequence of inhibiting the renin- angiotensin- aldosterone system, changes in renal function may be anticipated in susceptible individuals. Caution should be taken for these
￼patients.<br><br>

<strong>Pregnancy & lactation:</strong> When pregnancy is detected, this drug should be discontinued as soon as possible. It should not be used in lactation also. 
<br><br>

<strong>Dosage & admin:</strong> The usual starting dose of this combination preparation is telmisartan 40mg once daily; blood pressure response is dose related over the range of 40-80mg. Hydrochlorothiazide is effective in doses of 12.5mg to 50mg once daily and can be given at doses of 12.5mg to 25mg.
It is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy. Telmisartan combination therapy may be administered with other antihypertensive drugs & it also may be administered with or without food.<br><br>

<strong>Drug inter:</strong> Digoxin levels be monitored when initiating, adjusting & discontinuing telmisartan. Alcohol, barbiturates, anti-diabetic drugs may interact with thiazide diuretics.   </p>
          </div><!-- collapsible -->




<div data-role="collapsible"> <!-- collapsible -->
    <h3>MITOSAN 40 Plus Tab. Sandoz/Novartis</h3>
    <p>Telmisartan INN 40mg & hydrochlorothiazide BP 12.5mg/tablet. 20's pack: 250.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MITOSAN 80 Plus Tab. Sandoz/Novartis</h3>
    <p>Telmisartan INN 80mg & hydrochlorothiazide BP 12.5mg/tablet. 20's pack: 400.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="VALSARTAN" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  VALSARTAN + HYDROCHLOROTHIAZIDE </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> VALSARTAN + HYDROCHLOROTHIAZIDE: Tablet  </h3>
                <p> Combination preparations of valsartan and hydrochlorothiazide are available in two fixed presentations, viz: i. valsartan INN USP 80mg + hydrochlorothiazide BP 12.5mg, and ii. valsartan INN USP 160mg + hydrochlorothiazide BP 12.5mg. Mode of action: See above under the text of 'candesartan + hydrochlorothiazide' combined prepn. Ind: These combined preparations are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy of hypertension.<br><br>

<strong>C/I:</strong> Hypersensitive to any component of this product; particularly hydrochlorothiazide component is contraindicated in patients with anuria or hypersensitivity to other sulfonamide- derived drugs. Pregnancy & lactation.
<br><br>

<strong>S/E:</strong> Allergic reaction, anaphylaxis, asthenia and dependent edema. 
Palpitations, syncope, and tachycardia. Flushing, rash, sunburn and increased sweating. Increased appetite, constipation, dyspepsia, flatulence, dry mouth, dehydration, nausea, abdominal pain, & vomiting. Arthralgia, gout, muscle cramps, muscle weakness, arm pain, and leg pain etc. Precautions: Renal insufficiency: There is no apparent correlation between renal function (measured by creatinine clearance) and exposure (measured by AUC) to valsartan in patients with different degrees of renal impairment.<br><br>

<strong>Pregnancy & lactation:</strong> When pregnancy is detected, this drug should be discontinued as soon as possible. It should not be used in lactation also.<br><br> 

<strong>Dosage & admin:</strong> The recommended starting dose of valsartan is 80mg or 160mg once daily
when used as monotherapy in patients who are not volume depleted. Patients requiring greater reductions may be started at a higher dose. Valsartan may be used over a dose range of 80mg to 320mg daily, administered once-a-day. A patient whose blood pressure is not adequately controlled with valsartan monotherapy, patient may be switched over to valsartan combination formula with hydrochlorothiazide. Hydrochlorothiazide is effective in doses of 12.5 to 50mg daily, and can be given at doses of 12.5mg to 25mg in combination with valsartan (valsartan 80mg/hydrochlorothiazide 12.5mg or valsartan 160mg/ hydrochlorothiazide 12.5mg) once daily. If blood pressure remains uncontrolled after about 3-4 weeks of treatment, either valsartan or both components may be.
increased depending on clinical response. Children: The efficacy and effectiveness of this combination preparation have not been established in patients younger than 18 years of age.<br><br>
<strong></strong>
<strong>Drug inter:</strong> See above under the text of 'valsartan' and 'hydrochlorothiazide' separately.
   </p>
              </div><!-- collapsible -->




<div data-role="collapsible"> <!-- collapsible -->
    <h3>CO-DIOVAN 80/12.5 Tab. Novartis</h3>
    <p>Valsartan INN USP 80mg + hydrochlorothiazide BP 12.5mg/tablet (f.c). 28's pack: 1220.24 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CO-DIOVAN 160/12.5 Tab. Novartis</h3>
    <p>Valsartan INN USP 160mg + hydrochlorothiazide BP 12.5mg/tablet (f.c). 28's pack: 1648.08 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DISYS PLUS Tab. Healthcare</h3>
    <p>Valsartan INN USP 80mg + hydrochlorothiazide BP 12.5mg/tablet (f.c). c).
TELMISARTAN + HYDROCHLOROTHIAZIDE: Tablet</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VALZIDE 80/12.5 Tab. Renata</h3>
    <p>Valsartan INN USP 80mg + hydrochlorothiazide BP 12.5mg/tablet (f.c).
20's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VALZIDE 160/12.5 Tab. Renata</h3>
    <p>Valsartan INN USP 160mg + hydrochlorothiazide BP 12.5mg/tablet (f.c). 20's pack: 320.00 MRP</p>   
</div><!-- collapsible -->

              
      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Nitrates: Coronary vasodilators" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Nitrates: Coronary vasodilators   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

     <ul data-role="listview" data-inset="true" data-theme="b">        
     
       
        <li><a href="#Glyceryl trinitrate">Glyceryl trinitrate</a></li> 
        <li><a href="#Isosorbide dinitrate">Isosorbide dinitrate</a></li> 
        <li><a href="#Isosorbide mononitrate">Isosorbide mononitrate</a></li> 
                
</ul>

   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Glyceryl trinitrate" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Glyceryl trinitrate  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLYCERYL TRINITRATE: Tablet/ Injection / Ointment/Inhalation or Spray  </h3>
                <p>  <strong>Ind:</strong> Prophylaxis and treatment of angina pectoris including variant angina, left ventricular failure.<br><br> 

                <strong>C/I:</strong> Marked anaemia, head trauma, cerebral haemorrhage, closed angle glaucoma.<br><br>

<strong>S/E:</strong> Throbbing headache, flushing, dizziness, tachycardia, postural hypotension.<br><br>

<strong>Caution:</strong> Hypotensive condition, Development of tolerance.
<br><br>
<strong>Dosage & admin:</strong> Sublingually: 0.5-1mg, repeat as requird.
By mouth: 2.6-6.4mg as sustained release tablets, 2-3 times daily.
By i.v infusion: 10-200mcg/min.
By spray: Treatment or prophylaxis of angina, spray 1-2 dose under tongue & then close mouth.  </p>
              </div><!-- collapsible -->





<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGICARD Tab. Drug Inter.</h3>
    <p>Glyceryl trinitrate 0.5mg/tablet. 100's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGIST SR Tab. Acme</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet (sustained release).
30's pack: 120.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANRIL Tab. Square</h3>
    <p>Glyceryl trinitrate 0.5mg/tablet.
100's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANRIL SR Tab. Square</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet (sustained release).
30's pack: 120.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>G.T.N Inj. DBL/Globex</h3>
    <p>Glyceryl trinitrate 5mg/ml; 10ml amp: i.v infusion 10ml amp x 1's pack: 163.97 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NATO SR Tab. White Horse</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet (sustained release).
50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NIDOCARD RETARD Tab. Drug Inter</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/capsule (sustained release). 100's pack: 400.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NIDOCARD Spray Drug Inter.</h3>
    <p>Glyceryl trinitrate, aerosol spray, 400mcg/metered dose.
200 doses unit: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITRIN SR Tab. Healthcare</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet (sustained release).
30's pack: 105.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITRIN SR Cap. Healthcare</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/capsule (sustained release).
60's pack: 279.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITROCAP LA Cap. Orion</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/capsule (sustained release pellets).
30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITROCARD Tab. Aristopharma</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet. 50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITRODIL Cap. Medimet</h3>
    <p>Glyceryl trinitrate (diluted nitroglycerine) 2.6mg/capsule.
50's pack: 232.50 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITROMINT Retard Tab. Egis/City Overseas</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet (controlled release).
30's pack: 135.000 TP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITROMINT Spray Egis/City Overseas</h3>
    <p>Glyceryl trinitrate, aerosol spray, 400mcg/metered dose.
180 doses unit: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITRONAL Spray Pohl Boskamp/
Medinam</h3>
    <p>Glyceryl trinitrate, aerosol spray, 400mcg/metered dose.
200 doses unit: 245.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITRONAL Inj. Pohl Boskamp/ Medinam</h3>
    <p>Glyceryl trinitrate 1mg/ml; 10m1 ampoule & 50ml vial: injection for infusion 10m1 (10mg) amp x l's pack: 100.00 MRP
50ml (50mg) vial x l's pack: 340.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITRO-SR Tab. UniHealth/UniMed</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet (sustained release).
30's pack: 120.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NITROVAS SR Tab. Popular</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet (sustained release).
30's pack: 105.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TROCER 2.6 SR Cap. Incepta</h3>
    <p>Glyceryl trinitrate (nitroglycerine) 2.6mg/capsule (sustained release).
30's pack: 120.00 MRP</p>   
</div><!-- collapsible -->

     

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Isosorbide dinitrate" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Isosorbide dinitrate   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> ISOSORBIDE DINITRATE  </h3>
                <p> ISOSORBIDE DINITRATE: Tablet/ Capsule/Injection.<br><br>
                
                <strong>Ind:</strong> Prophylaxis and treatment of angina; left ventricular failure.<br><br>

                <strong>C/I,S/E, Cautions:</strong> same as glyceryl trinitrate. Dose: Acute attack, 5-10mg sublingually.
                By mouth, prophylaxis, angina 30-120mg daily in 3 or 4 divided doses; left ventricular failure, 40-160mg upto 240mg daily if required, in divided doses.
                By i.v infusion, 2-10mg/hour, higher
                doses upto 20mg/hour may be required.
                  </p>
              </div><!-- collapsible -->




<div data-role="collapsible"> <!-- collapsible -->
    <h3>ESORDIN Tab. Square</h3>
    <p>Isosorbide dinitrate 10mg/tablet 100's pack: 35.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ISOCARD Tab. Sonear</h3>
    <p>Isosorbide dinitrate 10mg/tablet 100's pack: 35.00 MRP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Isosorbide mononitrate" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Isosorbide mononitrate  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> ISOSORBIDE MONONITRATE: Tablet  </h3>
                <p>  <strong>Ind:</strong> Prophylaxis and treatment of angina; adjunct in congestive heart failure.<br><br>

<strong>C/I; S/E; Cautions:</strong> See under 'glyceryl trinitrate'. Dose: Initially 20mg 2-3 times daily or 40mg twice daily (10mg twice daily in those who have not previously received nitrates); up to 120mg daily in divided doses if required.  </p>
              </div><!-- collapsible -->




<div data-role="collapsible"> <!-- collapsible -->
    <h3>A-CARD Tab. Acme</h3>
    <p>Isosorbide mononitrate 20mg/tablet 100's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGIFIX 20 Tab. Incepta</h3>
    <p>Isosorbide-5-mononitrate 20mg/tablet 50's pack: 71.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ESMO Tab. Square</h3>
    <p>Isosorbide mononitrate 20mg/tablet 100's pack: 142.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ESMO LA Cap. Square</h3>
    <p>Isosorbide mononitrate 50mg/capsule (long acting) 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>IMOCARD Tab. UniHealth</h3>
    <p>Isosorbide mononitrate 20mg/tablet 100's pack: 142.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ISM Tab. Aristopharma</h3>
    <p>Isosorbide mononitrate 20mg/tablet 100's pack: 140.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MONATE Tab. Beximco</h3>
    <p>Isosorbide mononitrate 20mg/tablet 100's pack: 142.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MONITEN Tab. ACI</h3>
    <p>Isosorbide mononitrate 20mg/tablet 100's pack: 142.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MONOCARD Tab. Drug Inter.</h3>
    <p>Isosorbide mononitrate 20mg/tablet 100's pack: 142.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MONOCARD SR Cap. Drug Inter.</h3>
    <p>Isosorbide mononitrate 50mg/capsule (sustained release) 50's pack: 354.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MONOTRATE Tab. Sun Pharma</h3>
    <p>Isosorbide-5-mononitrate 20mg/tablet 50's pack: 71.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MONOTRATE OD Tab. Sun Pharma</h3>
    <p>Isosorbide-5-mononitrate 50mg/tablet 30's pack: 123.90 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PENTACARD Tab. Altana Pharma / Medinam</h3>
    <p>Isosorbide mononitrate 20mg/tablet 20mg x 60's pack: 400.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>UNICARD Tab. Sonear</h3>
    <p>Isosorbide mononitrate 20mg/tablet 100's pack: 140.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Calcium-channel blockers" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Calcium-channel blockers   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

     <ul data-role="listview" data-inset="true" data-theme="b">        
    
        <li><a href="#Amlodipine">Amlodipine</a></li> 
        <li><a href="#Diltiazem hydrochloride">Diltiazem hydrochloride</a></li> 
        <li><a href="#Lercanidipine hydrochloride">Lercanidipine hydrochloride</a></li> 
        <li><a href="#Nifedipine">Nifedipine</a></li> 
        <li><a href="#Nimodipine">Nimodipine</a></li> 
        <li><a href="#Verapamil hydrochloride">Verapamil hydrochloride</a></li> 
       
                
      </ul>

   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Amlodipine" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Amlodipine  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>  AMLODIPINE BESYLATE: Tablet </h3>
                <p> Amlodipine besilate is a dihydropyridine calcium channel blocker.<br><br>

<strong>Mode of action:</strong> As calcium antagonist amlodipine besilate inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The contractile process of cardiac muscle and vascular smooth muscle is dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. It acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.<br><br>

<strong>Ind:</strong> Essential hypertension, angina pectoris, vasospastic angina.<br><br>

<strong>C/I:</strong> Amlodipine is contraindicated in patients with a known sensitivity to dihydropyridines. It should not be used in cardiogenic shock, clinically significant aortic stenosis, unstable angina (excluding Prinzmetal's angina). It is also contraindicated in pregnant woman.<br><br>

<strong>S/E:</strong> The most common side-effects are associated with vasodilator action, such as, dizziness, flushing, headache, hypotension and peripheral oedema. Gastrointestinal disturbances, increased frequency of micturition, lethargy, eye pain and mental depression may also occur. A paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure may lead to cerebral or myocardial ischaemia or transient blindness. Gum hyperplasia, erythema multiforme also reported.<br><br>

<strong>Cautions:</strong> Caution should be taken in patients with hepatic impairment, during pregnancy and breast-feeding.<br><br>

<strong>Pregnancy & lactation:</strong> Use of amlodipine in pregnancy & lactation has yet not been established. <br><br>

<strong>Dosage & Admin:</strong>
Hypertension- usual dose is 5mg once daily; maximum dose is 10mg once daily; elderly patients with hepatic insufficiency may be started with 2.5mg once daily. In hypertension it may be used alone or in combination with other antihypertensive therapy.
Angina- 5-10mg once daily; using the lower dose in the elderly and in patients with hepatic insufficiency. Most patients require 10mg. Amlodipine may be taken without regard to meals.<br><br>

<strong>Drug inter:</strong> No significant drug interaction.   </p>
              </div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMDIN Tab. Alco Pharma</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 50's pack: 150.00 MRP 10mg x 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMDOCAL Tab. Beximco</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 90's pack: 360.00 IP 10mg x 30's pack: 180.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMDOPER Tab. Hallmark</h3>
    <p>Amlodipine 5mg/tablet. 5mg x 30's pack: 90.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMDOPIN Tab. Ziska</h3>
    <p>Amlodipine 5mg/tablet.5mg x 50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMLO Tab. Pharmadesh</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 50's pack: 150.00 MRP 10mg x 30's pack: 165.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMLOCARD Tab. Drug Inter.</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 100's pack: 450.00 MRP 10mg x 50's pack: 350.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMLODIN Tab. Jalalabad</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 50's pack: 150.00 MRP 10mg x 50's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMLOMARK 5 Tab. Marksman</h3>
    <p>Amlodipine 5mg/tablet. 5mg x 30's pack: 90.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMLOPIN Tab. Acme</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 30's pack: 120.00 MRP 10mg x 30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMLOSIN-5 Tab. Doctor's</h3>
    <p>Amlodipine 5mg/tablet. 5mg x 30's pack: 102.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMLOSUN Tab. Sun Pharma</h3>
    <p>Amlodipine 5mg/tablet. 5mg x 100's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMLOVAS Tab. Popular</h3>
    <p>Amlodipine 5mg/tablet.5mg x 28's pack: 98.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMLOWIDE Tab. Beacon</h3>
    <p>Amlodipine 5mg/tablet.5mg x 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMOCAL Tab. Opsonin</h3>
    <p>Amlodipine 5mg/tablet.5mg x 30's pack: 120.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMODIPIN Tab. Delta Pharma</h3>
    <p>Amlodipine 5mg/tablet.5mg x 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMPIL Tab. White Horse</h3>
    <p>Amlodipine 5mg/tablet.
5mg x 50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAB Tab. ACI</h3>
    <p>Amlodipine 5mg/tablet.
5mg x 50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CALCHEK Tab. General</h3>
    <p>Amlodipine 5mg/tablet. 5mg x 50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CALOCK Tab. Medimet</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 100's pack: 200.00 MRP 10mg x 100's pack: 375.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CALPIN Tab. Globe</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 50's pack: 150.00 MRP 10mg x 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CALVASC Tab. UniHealth</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 30's pack: 120.00 MRP 10mg x 30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAMLODIN Tab. Square</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 30's pack: 120.00 MRP 10mg x 30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARDIPIN Tab. Renata</h3>
    <p>Amlodipine 5mg/tablet.5mg x 50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CCB Tab. Orion</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 50's pack: 150.00 MRP 10mg x 50's pack: 275.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CORDIL Tab. Techno Drugs</h3>
    <p>Amlodipine 5mg/tablet.5mg x 30's pack: 90.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DIPLOR Tab. Ibn Sina</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 30's pack: 120.00 MRP 10mg x 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DOPIN Tab. Medicon</h3>
    <p>Amlodipine 5mg/tablet.
5mg x 30's pack: 120.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EMLON Tab. Bio-pharma</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 50's pack: 225.00 MRP 10mg x 30's pack: 165.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>HIPRE Tab. Pacific</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 50's pack: 200.00 MRP 10mg x 30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>HYPOTEN Tab. Cosmic</h3>
    <p>Amlodipine 5mg/tablet.
5mg x 30's pack: 105.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>IMPED Tab. Rephco</h3>
    <p>Amlodipine 5mg/tablet.
5mg x 50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>IPIN Tab. Chemist</h3>
    <p>Amlodipine 5mg/tablet.
5mg x 30's pack: 105.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOCARD Tab. Jayson</h3>
    <p>Amlodipine 5mg/tablet. 5mg x 50's pack: 151.50 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LODIPIN-5 Tab. Aristopharma</h3>
    <p>Amlodipine 5mg/tablet.
5mg x 50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOPIN Tab. Edruc</h3>
    <p>Amlodipine 5mg/tablet. 5mg x 30's pack: 90.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>M-CARD Tab. Zenith</h3>
    <p>Amlodipine 5mg/tablet. 5mg x 50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NELOD-5 Tab. Chemico</h3>
    <p>Amlodipine 5mg/tablet. 5mg x 50's pack: 250.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>RODIPINE Tab. Rasa</h3>
    <p>Amlodipine 5mg/tablet. 5mg x 50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SIDOPIN Tab. SK+F</h3>
    <p>Amlodipine 5mg/tablet.
5mg x 50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VASOPIN Tab. Silva</h3>
    <p>Arnlodipine 5mg & 10mg/tablet. 5mg x 30's pack: 90.00 MRP 10mg x 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VESOCAL Tab. Rangs Pharma</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 50's pack: 225.00 MRP 10mg x 30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>XELCARD Tab. Healthcare</h3>
    <p>Amlodipine 5mg & 10mg/tablet. 5mg x 30's pack: 120.00 MRP 10mg x 30's pack: 195.00 MRP</p>   
</div><!-- collapsible -->


              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Diltiazem hydrochloride" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Diltiazem hydrochloride   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> DILTIAZEM HCI: Tablet/Capsule  </h3>
                <p>  
<strong>Ind:</strong> prophylaxis and treatment of angina; hypertension.<br><br>

<strong>C/I:</strong> severe bradycardia, left ventricular failure, second- or third-degree AV block (unless pacemaker fitted), sick sinus syndrome; pregnancy (toxicity in animal studies); porphyria. <br><br>

<strong>S/E:</strong> bradycardia, sino-atrial block,
atrioventricular block, hypotension, malaise, headache, hot flushes, gastro-intestinal
disturbances, ankle oedema; rarely rashes (erythema multiforme reported); altered liver function tests; hepatitis and depression reported. Cautions: reduce dose in hepatic and renal impairment; heart failure or significantly impaired left ventricular function, mild bradycardia (avoid if severe), first degree AV block, or prolonged PR interval.<br><br>
<strong></strong>
<strong>Dose:</strong> Angina, 60mg 3 times daily (ederly initially twice daily); increased if necessary to 360mg daily (max. 480mg daily).
SR (sustained reliease) preparations- angina and mild to moderate hypertension, initially 90mg twice daily (elderly and in hepatic and renal impairment, dose form not appropriate for initial dose titration); increased if necessary to 120mg or 180mg twice daily.  </p>
              </div><!-- collapsible -->






<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARDIL Tab. Ibn Sina</h3>
    <p>Diltiazem hydrochloride 30mg & 60mg/tablet 30mg x 100's pack: 202.00 IP
60mg x 100's pack: 385.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARDIZEM Tab. Drug Inter.</h3>
    <p>Diltiazem hydrochloride 30mg & 60mg/tablet 30mg x 100's pack: 200.00 MRP 60mg x 100's pack: 380.00 MRP.</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARDIZEM-SR Cap. Drug Inter.</h3>
    <p>Diltiazem hydrochloride 90mg & 120mg/capsule (sustained release) 90mg x 50's pack: 250.00 MRP 120mg x 50's pack: 400.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DIAL Tab. Nipa</h3>
    <p>Diltiazem hydrochlor. 60mg/tablet 60mg x 100's pack: 380.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DILGEM Tab. Sonear</h3>
    <p>Diltiazem hydrochloride 30mg & 60mg/tablet. 30mg x 100's pack: 200.00 MRP 60mg x 100's pack: 350.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DILTIZEM-SR Tab. Square</h3>
    <p>Diltiazem hydrochloride 90mg/tablet (sustained release)90mg x 40's pack: 223.20 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DILZEM Tab. Sonear</h3>
    <p>Diltiazem hydrochloride 30mg & 60mg/tablet 30mg x 100's pack: 200.00 MRP
60mg x 100's pack: 350.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EVASCON Tab. Renata Diltiazem</h3>
    <p>hydrochloride 30mg & 60mg/tablet 30mg x 100's pack: 202.00 MRP 60mg x 100's pack: 385.00 MRP.</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LITIZEM Tab. Incepta Diltiazem</h3>
    <p>hydrochloride 30mg & 60mg/tablet 30mg x 50's pack: 100.00 MRP 60mg x 30's pack: 114.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NEOCARD Tab. Beximco Diltiazem</h3>
    <p>hydrochlorride 30mg & 60mg/tablet. 30mg x 100's pack: 200.00 IP 60mg x 100's pack: 380.00 IP.</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TIZEM Tab. Delta</h3>
    <p>Diltiazem hydrochloride 30mg & 60mg/tablet 30mg x 100's pack: 200.00 MRP
60mg x 50's pack: 190.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Lercanidipine hydrochloride" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Lercanidipine hydrochloride  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>  LERCANIDIPINE HCI: Tablet </h3>
                <p>  Lercanidipine is an antihypertensive drug. It is a selective calcium channel blocker of the dihydropyridine group. <br><br>

                <strong>Mode of action:</strong> Lercanidipine acts by selective inhibition of the transmembrane influx of calcium into smooth muscle. Its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle, thus lowering total peripheral resistance. Lercanidipine is endowed with a prolonged antihypertensive activity because of its high membrane partition coefficient, and is devoid of negative inotropic effects due to its high vascular selectivity.<br><br>

<strong>Ind:</strong> Mild to moderate essential hypertension. <br><br>

<strong>C/I:</strong> Lercanidipine is contraindicated in patients with left ventricular outflow tract obstruction, untreated congestive cardiac failure, unstable angina pectoris, within 1 month of a myocardial infarction and known hypersensitivity to any dihydropyridine. Lercanidipine should not be taken with grapefruit juice.<br><br>

<strong>S/E:</strong> Treatment with lercanidipine is generally well tolerated. The most common side effects are related to the vasodilator properties of lercanidipine such as flushing, peripheral edema, headache, dizziness and asthenia. Other side effects, which occurred in less than 1% of patients include fatigue; G1 disturbances such as dyspepsia, nausea, vomiting, epigastric pain and diarrhea. polyurea, rash, somnolence and myalgia.<br><br>

<strong>Precaution:</strong> Special care should be exercised when lercanidipine is used in patients with sick sinus syndrome, left ventricular dysfunction and ischaemic heart disease.<br><br>

<strong>Pregnancy & lactation:</strong> Since there is no clinical data with lercanidipine in pregnancy, it should not be administered during pregnancy or to woman with child bearing potential unless effective contraception is used.
Lercanidipine is highly lipophilic and distribution in milk may be expected. Therefore, it should not be administered to nursing mother.<br><br>

<strong>Dosage & admin: Adult:</strong> 10mg orally once daily at least 15 minutes before meals; the dose may be increased to 20mg depending on the individual patient's response. It may take about 2 weeks before the maximal antihypertensive effect is apparent.
Some individuals, not adequately controlled on a single antihypertensive agent, may benefit from the addition of lercanidipine to therapy with a beta-adrenoceptor blocking drug (atenolol), a diuretic (hydrochlorothiazide) or an ACE inhibitor (rmaipril).<br><br>

<strong>Use in children:</strong> Use in children under the age of 18 years is not currently recommended.
Use in renal or hepatic dysfunction: Special care should be exercised in patients with mild to moderate renal or hepatic dysfunction. Dosage above 20mg daily must be approached with caution. Lercanidipine is not recommended for use in patients with severe hepatic or renal dysfunction.
Drug inter: Concomitant treatment of lercanidipine with cyclosporin, phenytoin, carbamazepine, rifampicin, ketoconazole, itraconazole, ritonavir, erythromycin, troleandomycin, and midazolam should be avoided. Caution should be exercised when lercanidipine is co-prescribed with astemizole, amiodarone, quinidine, cimetidine, metoprolol and simvastatin.
￼  </p>
              </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>LARCADIP Tab. Incepta</h3>
    <p>Lercanidipine hydrochloride INN 10mg/tablet. 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LARCAN Tab. Opsonin</h3>
    <p>Lercanidipine hydrochloride INN 10mg/tablet. 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Nifedipine" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Nifedipine  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> NIFEDIPINE: Tablet/Capsule/ Injection  </h3>
                <p>  It relaxes vascular smooth muscles and dilates coronary and peripheral arteries. Unlike verapamil it has no anti-arrhythmic activity.<br><br>

<strong>Ind:</strong> Prophylaxis and treatment of angina, hypertension, raynauds phenomenon.<br><br>

<strong>C/I:</strong> Women of child bearing age.<br><br>

<strong>S/E & Cautions:</strong> See under amlodipine. Adult: 5-20mg 3 times daily with or after meals. If immediate effect required, bite capsule & allow liquid to retain in the mouth. Child: Not recommended.  </p>
              </div><!-- collapsible -->





<div data-role="collapsible"> <!-- collapsible -->
    <h3>NICODIN Tab. Jalalabad</h3>
    <p>Nifedipine 10mg/tablet
100's pack: 34.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NIDIPINE Tab. Square</h3>
    <p>Nifedipine 10mg/tablet
200's pack: 68.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NIDIPINE-SR Tab. Square</h3>
    <p>Nifedipine 20mg/tablet (sustained release)
100's pack: 64.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NIFECAP Cap. Drug Inter.</h3>
    <p>Nifedipine 10mg in soft capsule. 10mg x 30's pack: 63.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NIFIN Tab. Acme</h3>
    <p>Nifedipine 10mg/tablet
100's pack: 34.00 MRP</p>   
</div><!-- collapsible -->
        

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->





<!-- /................page............................ -->



<div data-role="page" id="Nimodipine" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Nimodipine  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> NIMODIPINE: Tablet  </h3>
                <p> Nimodipine is a calcium channel blocker. It is available as nimodipine BP 30mg film-coated tablet.<br><br>

<strong>Mode of action:</strong> The contractile process of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. Nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood-brain barrier. It is therefore preferable in treating subarachnoid hemorrhage (SAH) patients.<br><br>

<strong>Ind:</strong> For the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition.<br><br>

<strong>C/I:</strong> Not known.<br><br>

<strong>S/E:</strong> Although side effects from nimodipine are not common, the following can occur, such as: headache, dizziness or light-headedness, flushing (feeling of warmth), heartburn, fast heartbeat, slow heartbeat, upset stomach, stomach pain, constipation, depression, feeling low, or the 'blues' unusual bruising or bleeding. Precautions: Blood pressure: Blood pressure should be carefully monitored during treatment with nimodipine based on its known pharmacology and the known effects of calcium channel blockers.
Hepatic disease: In patients with impaired hepatic function, the metabolism of nimodipine is decreased. In these patients nimodipine should be given in a lower dose; blood pressure and pulse rate of the patients should be monitored closely. <br><br>

<strong>Pregnancy & lactation:</strong> Large doses of nimodipine have been shown to cause birth defects in animals. Human studies have not been done. However, in pregnancy it should not be given.
Nimodipine may pass into breast milk but has not been reported to cause problems; caution is advised.<br><br>

<strong>Dosage & admin:</strong> Initial dose is 60mg (2 tablets) every four hours for 21 consecutive days, preferably not less than one hour before or two hours after meals. Oral nimodipine therapy should be commencing within 96 hours of the subarachnoid hemorrhage.   </p>
              </div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>NIMOCAL Tab. Square</h3>
    <p>Nimodipine BP 30mg/tablet (f.c). 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<div data-role="page" id="Verapamil hydrochloride" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Verapamil hydrochloride  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> VERAPAMIL HCI: Tablet.  </h3>
                <p> It is a calcium channel blocker & acts by interfering with the slow inward depolarising calcium flow particularly in the S.A and A.V nodal cells.<br><br>

<strong>Ind:</strong> Supraventricular arrhythmias, paroxysmal ventricular tachyarrythmias, angina, hypertension. C/I : Hypotension, bradycardia, second and third degree heart block, sick sinus syndrome, cardiogenic shock, sino-atrial block, uncompensated heart failure, atrial flutter or fibrillation complicating Wolff-parkinson white (WPW) syndrome.<br><br>

<strong>S/E:</strong> Constipation, less commonly nausia, vomiting, flushing, headache, dizziness, fatigue, ankle oedema. After intravenous administration, hypotension, bradycardia, heart block, ventricular fibrillation and asystole.
<br><br>

<strong>Dosage & admin:</strong> By mouth: Supraventricular arrhythmias, 40-120mg t.d.s. Angina, 80- 120mg t.d.s. daily. Hypertension, 240-480mg daily in 2-3 divided doses.<br><br><strong></strong>
By slow i.v injection: Over 2 minutes 5-10mg (preferably with E.C.G. monitoring); in paroxysmal tachyarrhythmias a further 5mg after 5-10 minutes if required.<br><br>

<strong>Note:</strong> Verapamil should not be injected into patients recently treated with beta-blockers because of the risk of hypotension and asystole. It is suggested an interval of 30 minutes before giving beta-blocker is sufficient but this too is open to doubt.   </p>
              </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>AKILEN Tab. Medochemie/ Hyeimpex</h3>
    <p>Verapamil hydrochloride 80mg/tablet. 80mg x 50's pack: 268.00 MRP</p>   
</div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGIMIL Tab. Medimet Verapamil</h3>
    <p>hydrochloride 40mg & 80mg/tablet. 40mg x 100's pack: 225.00 MRP 80mg x 100's pack: 425.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGIMIL SR Tab. Medimet</h3>
    <p>Verapamil hydrochloride 240mg/tablet (sustained release).
240mg x 15's pack: 105.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VERACAL Tab. Incepta</h3>
    <p>Verapamil hydrochloride 80mg/tablet. 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VERACAL SR 180 Tab. Incepta</h3>
    <p>Verapamil hydrochloride 180mg/tablet (sustained release).180mg x 30's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VERACAL SR Tab. Incepta</h3>
    <p>Verapamil hydrochloride 240mg/tablet (sustained release).
240mg x 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VERACAL Inj. Incepta</h3>
    <p>Verapamil hydrochloride 2.5mg/ml; 2m1 ampoule: injection.
2ml amp (5mg) x 5's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VERAMIL Tab. Rangs Pharma</h3>
    <p>Verapamil hydrochloride 80mg/tablet. 50's pack: 150.00 MRP
    </p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VERAMIL SR Tab. Rangs Pharma</h3>
    <p>Verapamil hydrochloride 240mg/tablet (sustained release).
240mg x 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->


              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

	
<!-- /................page............................ -->



<div data-role="page" id="Potassium-channel activators" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Potassium-channel activators  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> NICORANDIL: Tablet  </h3>
                <p> Nicorandil INN 5mg & 10mg/tablet.

<strong>Mode of action:</strong> It is a potassium-channel activator, and causes both arterial and venous vasodilation.<br><br>

<strong>Ind:</strong> Prevention and long-term treatment of
chronic stable angina pectoris.<br><br>

<strong>C/I:</strong> Cardiogenic shock. Left ventricular failure with low filling pressure. Hypotension.<br><br>

<strong>S/E:</strong> Headache; cutaneous vasodilatation with flushing; nausea, vomiting; dizziness, weakness also reported; rarely oral ulceration and myalgia; at high dosage reduction in blood pressure and/or increase in heart rate; angioedema, hepatic dysfunction also reported.<br><br>

<strong>Precautions:</strong> It should be used with caution in patients with hypovolaemia, low systolic pressure, acute pulmonary oedema, acute myocardial infarction with acute left ventricular failure and low filling pressure.<br><br>

<strong>Pregnancy & lactation:</strong> It should not be given to pregnant women as well as lactating mothers, as there is no evidence of safety profile for these cases.<br><br>

<strong>Dosage & admin:</strong> Initially 10mg twice daily    </p>
              </div><!-- collapsible -->




<div data-role="collapsible"> <!-- collapsible -->
    <h3>CORANGI-10 Tab. UniHealth</h3>
    <p>Nicorandil INN 10mg/tablet. 10mg x 30's pack: 105.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NICOR Tab. Orion</h3>
    <p>Nicorandil INN 10mg/tablet. 10mg x 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Misc. Antianginal & anti-ischaemic drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Misc. Antianginal & <br> anti-ischaemic drugs   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> TRIMETAZIDINE: Tablet  </h3>
                <p> 
TRIMETAZIDINE: Tablet<br><br>
Trimetazidine is an antianginal and anti-ischaemic agent that display anti-ischaemic effects without inducing haemodynamic changes and improves the status of the ischaemic myocardium.
It is available as trimetazidine dihydrochloride INN 20mg/tablet (f.c) and 35mg/tablet (modified release).<br><br>

<strong>Mode of action:</strong> By preserving the energy metabolism in cells exposed to hypoxia or ischemia, trimetazidine prevents a decrease in intracellular ATP levels, thereby ensuring the proper functioning of ionic pumps and transmembranous sodium-potassium flow while maintaining cellular homeostasis. The disturbances of tissue oxygen supply during ischemia decrease mitochondrial ATP production and increase the generation of free radicals (02-, OH-). By diminishing the bioavailability of free radicals, trimetazidine lessens all their toxic effects. Trimetazidine acts on the inactivation of enzymatic membrane proteins; it antagonizes free radical-induced stimulations of phospholipase A2 and thromboxane synthetase.<br><br>

<strong>Ind:</strong> Trimetazidine is indicated in- i. prophylactic treatment of episodes of angina pectoris and sequelae of infarction 'heart failure'; ii. adjuvant symptomatic treatment of vertigo and tinnitus; iii. adjuvant treatment of the decline of visual acuity and visual field disturbances, presumably of vascular origin.<br><br>

<strong>C/I:</strong> Hypersensitivity to trimetazidine.<br><br>

<strong>S/E:</strong> Rare cases of gastrointestinal disorders, nausea, headache and vertigo. The side effects are mild and non-spcific.<br><br>

<strong>Precautions:</strong> Not recommended in pregnancy and nursing mother.<br><br>

<strong>Pregnancy & lactation:</strong> Studies in animals have not demonstrated any teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
There is no information on the secretion of trimetazidine into breast milk. So, in the absence of data, breastfeeding is not recommended during treatment.<br><br>

<strong>Dosage & admin:</strong> 20mg tablet preparations: 1 tablet 3 times daily after meals.
35mg tablet preparations: 1 tablet at mealtimes in the morning and evening.
No dosage adjustments are required in patients with impaired renal and hepatic function. <br><br>

<strong>Child:</strong> Not recommended.</p>
              </div><!-- collapsible -->




<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGIMET Tab. Orion</h3>
    <p>Trimetazidine dihydrochloride INN 20mg/tablet (f.c) 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGINOX Tab. General</h3>
    <p>Trimetazidine dihydrochloride INN 20mg/tablet (f.c) 30's pack: 90.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FEELNOR Tab. Incepta</h3>
    <p>Trimetazidine dihydrochloride INN 20mg/tablet (f.c) 50's pack: 90.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>METACARD MR Tab. Aristopharma</h3>
    <p>Trimetazidine dihydrochloride INN 35mg/tablet (modified release).35mg x 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TRIMET Tab. Drug Inter</h3>
    <p>Trimetazidine dihydrochloride INN 20mg/tablet (f.c) 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="Cerebral vasodilator & Neurosensory oxygenator drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Cerebral vasodilator & <br> Neurosensory oxygenator drugs  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ALMITRINE + RAUBASINE  </h3>
          <p>    </p>
        </div><!-- collapsible -->

      <div data-role="collapsible"> <!-- collapsible -->
          <h3>DUXIL Tab. Servier53</h3>
          <p>Almitrine bismesylate 30mg + Raubasine 10mg/tablet.<br><br>

<strong>Mode of action:</strong> It is a neurosensory oxyge-nator drug effective in cerebral insufficiency.<br><br>

<strong>Ind:</strong> Minor, age-related neurological disorders (such as disorders of memory, concentration etc); some visual disorders & disorders of the inner ear (such as hearing loss, dizziness, buzzing sounds in the ear) related to the ischaemic circulation. <br><br>

<strong>C/I:</strong> Known allergy to the drug. Severe liver disease. Don't give with MAOIs.
<br><br>

<strong>A/E:</strong> Mild gastrointestinal disorders, nausea, sensations of heaviness and burning in the stomach, diarrhea, or constipation. Insomnia, drowsiness, agitation, anxiety, dizziness. Palpitations. During long-term treatment (1 year or more), rarely, sensation of 'pins and needles', stinging, or numbness in the lower limbs, or weight loss and usually disappear after discontinuation of the treatment.<br><br>

<strong>Cautions:</strong> Do not exceed the recommended dose. During long-term treatment, if abnormal sensation in the lower limbs, or weight loss occurs, discontinue treatment and consult physician. Avoid concomitant use of other drugs containing almitrine.<br><br>

<strong>Pregnancy & lactation:</strong> It is not recommended in women during pregnancy & lactation unless the therapeutic benefits outweigh any potential risk. Dosage: 1 tablet once or twice daily (one in the morning & one in the evening). In case of missing dose, take the next dose at the normal time; do not take a double dose.<br><br>

<strong>Overdosage:</strong> In case of massive overdosage with cardio-respiratory signs gastric lavage and symptomatic supportive measures should be applied under close cardiorespiratory obser- vation with repeated monitoring of blood gases. 30's pack: 299.20 MRP</p>   
      </div><!-- collapsible -->
            
      </div><!-- collapsible-set -->


       <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> VINPOCETINE: Tablet/Injection.  </h3>
          <p> <strong>Ind:</strong> Mental and neurological symptoms of reversible cerebrovascular disturbances, viz. amnesia, aphasia, apraxia, locomotor disorders, vertigo, headache. Hypertensive encephalopathy, intermittent cerebrovascular insufficiency, cerebral endarteritis etc.<br><br>
          <strong>C/I:</strong> Pregnancy<br><br>
          <strong>S/E:</strong> Slight fall in blood pressure, occasional tachycardia<br><br>
          <strong>Dose:</strong> initially 1-2 tabs. 3 times daily; maintenance, 1 tab. 3 times daily.   </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAMITON Tab. Drug Inter</h3>
    <p>Vinpocetine (apovincaminic ethylester) INN 5mg/tablet.100's pack: 400.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAVINTON Tab. Richter/City Overseas</h3>
    <p>Vinpocetine (apovincaminic ethylester) 5mg/tablet.
50's pack: 350.00 TP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAVINTON Inj. Richter/City Overseas</h3>
    <p>Vinpocetine 10mg/2ml ampoule: injection Dose: In acute case, 10mg slow i.v or in infusion, daily 2 to 3 times, then followed by oral dose, 1-2 tabs t.i.d.10 amps pack: 408.70 TP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAVITON Tab. Opsonin</h3>
    <p>Vinpocetine (apovincaminic ethylester) INN 5mg/tablet.
50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CERENIN Tab. Ambee</h3>
    <p>Vinpocetine (apovincaminic ethylester) INN 5mg/tablet.
50's pack: 177.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CERETON Tab. General</h3>
    <p>Vinpocetine (apovincaminic ethylester) INN 5mg/tablet.
50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CERIVIN Tab. Beximco</h3>
    <p>Vinpocetine (apovincaminic ethylester) INN 5mg/tablet.
100's pack: 400.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VINCET Tab. SK+F</h3>
    <p>Vinpocetine (apovincaminic ethylester) INN 5mg/tablet.50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VINTON Tab. Aristopharma</h3>
    <p>Vinpocetine (apovincaminic ethylester) INN 5mg/tablet.
100's pack: 300.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="Peripheral vasodilator drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Peripheral vasodilator drugs   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CILOSTAZOL  </h3>
          <p>    </p>
        </div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>ZOCIL Tab. Beximco</h3>
    <p>Cilostazol INN 50mg & 100mg/tablet
Cilostazol is a quinolinone derivative. 

<strong>Mode of action:</strong> Cilostazol acts by specific inhibition of cellular phosphodiesterase III (PDE III) and suppreses cAMP degradation with a resultant 'increase in cAMP and decrease in intracellular calcium ion in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.<br><br>

<strong>Ind:</strong> It is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.<br><br>

<strong>C/I:</strong> Congestive heart failure of any severity; known or suspected hypersensitivity to any of its components.<br><br>

<strong>S/E:</strong> Cilostazol is well tolerated with some most common side effects such as headache, diarrhoea, vomiting, rash etc. A few less frequent side effects also been reported such as anorexia, face oedema etc.
<br><br>


<strong>Precautions:</strong> As grapefruit juice inhibits CYP3A4, avoid concurrent use with cilostazol. Renal impairment- the total activity of cilostazol and its metabolites is similar in subjects with mild to moderate renal impairment and in healthy subjects.<br><br>

<strong>Pregnancy & lactation:</strong> There are no adequate and well controlled studies in pregnant women, so use during pregnancy only if the potential benefit justifies the potential risk to the fefus. As cilostazol is secreted into the milk of experimental animals, there is potential risk for the nursing infants, so a decision should be made to discontinue nursing or to discontinue cilostazol.<br><br>

<strong>Dosage & admin:</strong> The recommended dosage is 100mg orally twice daily, taken at least half an hour before or two hours after breakfast and dinner. A dose of 50mg b.i.d should be considered during coadministration of inhibitors of CYP3A4 (e.g ketoconazole, itraconazole, erythromycin and diltiazem) and during coadministration of inhibitors of CYP2C19 (e.g omeprazole). Patients may respond as early as 2 to 4 weeks after the initiation of therapy but treatment for up to 12 weeks may be needed before a beneficial effect is experienced.<br><br>

<strong>Pediatric use:</strong> The safety and effectiveness of cilostazol in pediatric patients have not been established.<br><br>

<strong>Overdosage:</strong> Information on acute overdosage with cilostazol in humans is limited. The signs and symptoms of an acute overdose are severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmias. The patient should be carefully observed and given supportive treatment.<br><br>

<strong>Drug inter:</strong> Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increase the systemic exposure of cilostazol and/or its major metabolites. Patients concurrently treated with diltiazem may cause higher concentrations of cilostazol. There is no information with respect to the efficacy or safety of the concurrent use of cilostazol and clopidogrel. Short-term coadministration of aspirin with cilostazol showed an increase in inhibition of ADP-induced platelet aggregation; effects on long-term coadministration are unknown. Cilostazol did not inhibit the metabolism or the pharmacologic effects of warfarin following a single dose; effect of concomitant multiple dosing of warfarin or cilostazol on either drug is unknown. <br><br>

50mg x 30's pack: 450.00 IP
100mg x 20's pack: 500.00 IP</p>   
</div><!-- collapsible -->

              
      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>OXPENTIFYLLINE/PENTOXIFYLLINE   </h3>
          <p>  Ind: Peripheral vascular disease.<br><br>

<strong>C/I:</strong> Acute myocardial infarction, profuse bleeding, brain haemorrhage.
<br><br>

<strong>S/E:</strong> G.I disturbances (nausea, vomiting, stomach pain), tension, dizziness, headache, rarely flushing tachycardia; ralely pruritus and urticaria. 

<strong>Caution:</strong> Hypotension, coronary artery disease, porphyria.
<br><br>

<strong>Dose:</strong> Initial dose is 200mg 3 times daily (during the first week); the dose should be lowered to 100mg 3 times daily in the case of excessive blood pressure reduction, as well as in longterm treatment.
In slow release form 400mg tab. 2-3 times daily may be given. All dosages usually after meal.  </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>AGAPURIN Rtd Tab. Zentiva/City Overseas</h3>
    <p>Oxpentifylline 400mg/tablet (retard) 100's pack: 840.00 TP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>OXIFYL CR Tab. Square</h3>
    <p>Pentoxifylline 400mg/tablet (controlled release) 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TRENTAL Tab. Sanofi Aventis</h3>
    <p>Pentoxiphylline 400mg/tablet 30's pack: 303.30 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VASOLAX Tab. Beximco</h3>
    <p>Pentoxiphylline 400mg/tablet 30's pack: 210.00 IP</p>   
</div><!-- collapsible -->



              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Drugs for Muscular energy metabolism" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Drugs for Muscular energy metabolism   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> LEVOCARNITINE: Tablet/Syrup  </h3>
          <p> Levocarnitine is a naturally occurring substance required in mammalian energy metabolism. It is available in tablet & syrup form: i. levocarnitine USP 330mg/tablet, & ii. levocarnitine USP 100mg/ml of syrup.<br><br>

<strong>Mode of action:</strong> Levocarnitine plays role as carrier molecule in mammalian energy metabolism. It facilitates long-chain fatty acid transport & entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as energy substrate in all tissues except the brain. In skeletal and cardiac muscles, fatty acids are the main substrate for energy production. Ind: Chronic fatigue syndrome, heart disease, congestive heart failure, high cholesterol, intermittent claudication, kidney disease, dementia and memory impairment, Down syndrome, male infertility, hyperthyroidism.<br><br>

<strong>C/I:</strong> Not known.<br><br>

<strong>S/E:</strong> Generally levocarnitine is well tolerated. However, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur.<br><br>

<strong>Precautions:</strong> The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine.
<br><br>

<strong>Pregnancy & lactation:</strong> There is no adequate and well controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed.
Levocarnitine supplementation in nursing mothers has not been specifically studied. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment.<br><br>

<strong>Dosage & admin: Adults:</strong> 300mg 2 or 3 times daily, depending on clinical response. <br><br>

<strong>Infants & children:</strong> 50-100mg/kg/day in divided doses, with a maximum of 3gm/day. Dosage should begin at 50mg/kg/day. The exact dosage will depend on clinical response. Drug inter: Not known.   </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARNITAB Tab. Beximco</h3>
    <p>Levocarnitine USP 330mg/tablet 30's pack: 90.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARNITAB Syp. Beximco</h3>
    <p>Levocarnitine USP 100mg/ml: syrup. 100m1 bot: 100.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARNITEN Tab. Drug Inter.</h3>
    <p>Levocarnitine USP 330mg/tablet 48's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>L-CARNI Tab. General</h3>
    <p>Levocarnitine USP 330mg/tablet 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LENIT Tab. Delta</h3>
    <p>Levocarnitine USP 330mg/tablet
30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LENIT Syp. Delta</h3>
    <p>Levocarnitine USP 330mg/tablet 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LEVOCAR Syp. Square</h3>
    <p>Levocarnitine USP 100mg/ml: syrup
100m1 bot: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>OCARNIX Tab. Incepta</h3>
    <p>Levocarnitine USP 330mg/tablet 20's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>OCARNIX Syp. Incepta</h3>
    <p>Levocarnitine USP 100mg/ml: syrup
100m1 bot: 100.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



  <!-- /................page............................ -->



<div data-role="page" id="Inotropic sympathomimetics" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Inotropic sympathomimetics   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

    
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> DOBUTAMINE HCI: Injection  </h3>
          <p> 
          <strong>mode of action:</strong> Dobutamine hydrochloride injection is an inotropic agent whose primary activity results from stimulation of the b-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic and vasodilative effects. The drug is believed to be a direct agonist which, in animal studies, produces less increase in heart rate and less decrease in peripheral vascular resistance for
a given inotropic effect than does isoprenaline. Facilitation of atrioventricular conduction has been observed in human electrophysiologic studies in normal subjects and in patients with atrial fibrillation. Systematic vascular resistance is usually decreased with administration of dobutamine. Occasionally, minimal vasoconstriction has been observed.
The onset of action is within one to two minutes; however, as much as ten minutes may be required to obtain the peak effect of a particular infusion rate.<br><br>

<strong>Ind:</strong> Dobutamine hydrochloride injection is indicated in adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.<br><br>

<strong>C/I:</strong> Dobutamine hydrochloride injection is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and previous hypersensitivity to dobutamine.<br><br>

<strong>S/E:</strong> Many of the side-effects of dobutamine are a quantitative extension of the pharmacological actions. The following adverse effects have been reported. Increased heart rate, blood pressure, and ventricular ectopic activity. Approximately 5% of patients have had increase premature ventricular beats during infusions. These effects are dose related and their occurrence may require that the dose be reduced.
Misc. uncommon effects: The following adverse effects have been reported in 1-3% of patients-: nausea, headache, anginal pain, nonspecific chest pain, palpitations and shortness of breath. Hypersensitivity reactions including rash, fever, eosinophilia and bronchospasm. As with other catecholamines, decreases in serum potassium concentrations have occurred, rarely to hypokalaemic values.<br><br>

<strong>Warnings:</strong> Increase in heart rate or blood pressure- dobutamine may cause a marked increase in heart rate or blood pressure, especially systolic pressure. Reduction of dosage usually reserves these effects promptly. Because dobutamine facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response. patients with preexisting hyperten-sion appear to face an increased risk of developing an exaggerated
pressor response.<br><br>

<strong>Ectopic activity:</strong> Dobutamine may precipitate or exacerbate ventricular ectopic activity, but it rarely has caused ventricular tachycardia. Anaesthetics: The myocardium may be sensitised to the effect of dobutamine by cyclopropane or halogenated hydrocarbon anaesthetics, and these should be avoided.
Dobutamine hydrochloride injection solution contains sodium metabisulfite, whcih may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people.
Precautions: During the administration of dobutamine, as with any adrenergic agent, ECG and blood pressure shuold be continuously monitored. In addition, pulmonary wedge pressure and cardiac output should be monitored whenever possible to aid in the safe and effective infusion of dobutamine.
Hypovolaemia should be corrected with suitable volume expanders before treatment with dobutamine is instituted.
In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to instituting therapy with dobutamine.
Animal studies indicate that dobutamine may be ineffective if the patient has recently received a beta-blocking drug. In such case, the peripheral vascular resistance may increase.
No improvement may be observed in the presence of marked mechanical obstruction, such as severe valvular aortic stenosis.<br><br>

<strong>Pregnancy & lactation:</strong> Since there are no adequate and well-controlled studies in pregnant women, dobutamine hydrochloride should not be used during pregnancy unless the potential benefits outweigh the potential risk to the fetus. As it is not known if dobutamine is secreted into the breast milk, the use of dobutamine in lactating women should take into account the potential harmful effects to the infant.<br><br>

<strong>Dosage & admin: Adults:</strong> The rate of infusion needed to increase cardiac output usually ranges from 2.5-15mcg/kg/min. On rare occasions, infusion rates up to 40mcg/kg/min have been required to obtain the desired effect.
Dobutmaine causes a dose related improvement in the cardiac output in patients with congestive heart failure. However, the possibility of intensifying myocardial ischaemia should be borne in mind and the lowest effective dose infused.<br><br>

<strong>Use in children:</strong> The safety and efficacy of dobutamine for use in children have not been studied.
Dilution for i.v infusion: Dobutamine hydrochloride injection must be diluted at the time of administration to at least 50m1 solution, such as in 5% or 10% Dextrose injection, 5% Dextrose & 0.45% or 0.9% Sodium chloride injection, or 0.9% Sodium chloride injection, Lactated Ringer's injection & Sodium lactate injection. Although chemically stable for 24 hours, prepared solutions should be used immediately after dilution. The rate of administration and the duration of therapy should be adjusted according to the patient's response, as determined by heart rate, presence of ectopic activity, blood pressure, urine flow, and whenever possible, measure- ment of central venous or pulmonary wedge pressure and cardiac output.
Concentrations up to 5000mcg/ml have been administered to humans (250mg/50ml). The final volume administered should be determined by the fluid requirements of the patient.<br><br>

<strong>Note:</strong> Do not add dobutamine hydrochloride injection to 5% sodium bicarbonate injection or any other strongly alkaline solutions. Dobutamine hydrochloride should not be used in conjunction with other agents or diluents containing sodium bisulfite.<br><br>

<strong>Overdosage:</strong> Overdoses of dobutamine have been reported rarely. The following is provided to serve as a guide if such an overdose is encountered.<br><br>

<strong>Signs & symptoms:</strong> Toxicity from dobutamine hydrochloride is usually due to excessive cardiac b-receptor stimulation. The symptoms of toxicity may include anorexia, nausea, vomiting, tremor, anxiety, palpitations, headache, shortness of breath and anginal and nonspecific chest pain. The positive inotropic and chronotropic effects of dobutamine on the myocardium may cause hypertension, tachyarrhythmias, myocardial ischaemia, and ventricular fibrillation. Hypotension may result from vasodilation. Treatment- Because the duration of action of dobutamine is short, reducing the rate of administration or temporarily discontinuing dobutamine therapy until the patients condition stabilises is usually adequate. However, in managing overdosage, consider the posibility of multiple durg overdoses, interaction among drugs, and unusual drug kinetics in the patient's body. The initial actions to be taken in a dobutamine hydrochloride overdose are- discontinuing administration, establishing an airway, and ensuring oxygenation and ventilation. Resuscitative measures should be initiated promptly. Severe ventricular tachyarrhythmias may be successfully treated with propranolol or lignocaine. Hypertension usually responds to a reduction in dose or discontinuation of therapy. Protect the patient's airway and support ventilation and perfusion. If needed, meticulously monitor and maintain the patient's vital signs, blood gases, serum electrolytes etc. (within acceptable limits). </p>
        </div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>DOBUJECT Inj. Schering Oy/ Tajarat</h3>
    <p>Dobutamine hydrochloride 250mg/5ml ampoule: injection for i.v infusion.
250mg (5ml) amp:</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DOBUTAMINE Inj. Abbott/ UniHealth</h3>
    <p>Dobutamine hydrochloride 250mg/20ml ampoule: injection for i.v infusion.
250mg (20ml) amp: 388.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DOBUTAMINE Inj. DBL/Globex</h3>
    <p>Dobutamine hydrochloride 250mg/20ml vial: injection for i.v infusion. 250mg (20ml) vial: 470.40 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->


       <div data-role="collapsible-set" data-theme="e">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>DOPAMINE HYDROCHLORIDE : Injection   </h3>
          <p>  Ind: Cardiogenic shock in infarction or cardiac surgery
C/I: Tachyarrhythmia, phaeochromo-cytoma
S/E: Nausea and vomiting, peripheral vasoconstriction, hypotension, hypertension, tachycardia
Cautions: Correct hypovolaemia; low dose in shock due to acute myocardial infarction.
Dose: By i.v infusion, 2-5mcg/kg/min. initially. Note: Dosage of dopamine is critical, since although low doses induce vasodilatation and increase renal perfusion, higher doses (more than 5mcg/kg/min) lead to vasoconstriction and may exacerbate heart failure, so the dosage regimen should be carefully maintained.
  </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>DOPAMINE Inj. Abbott/UniHealth</h3>
    <p>Dopamine hydrochloride 200mg/5ml ampoule: injection 1 amp pack: 62.20 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DOPAMINE Inj. DBL/Globex</h3>
    <p>Dopamine hydrochloride 200mg/5ml ampoule: injection
1 amp pack: 78.54 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="Vasoconstrictor sympathomimetics" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Vasoconstrictor sympathomimetics   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>DAFLON Tab. Servier</h3>
          <p>  Each tablet contains 500mg- micronized purified flavonoid fraction corresponding to- diosmine 90%, flavonoids expressed as hesperidin 10%: coated tablet.<br><br>

<strong>Ind:</strong> This medicine is a venotonic (increases venous tone) and a vasculoprotector (increases resistance in small blood vessels). It is recommended for treating venous circulation disorders (swollen legs, pain, restless legs) and for treating symptoms due to acute haemorrhoidal attack.<br><br>

<strong>S/E:</strong> Some cases of routine gastric disorders and neurovegetative disorders (feeling of discomfort) have been reported, not requiring discontinuation of treatment. (Report any untoward or undesirable effect to your doctor or pharmacist which has not been mentioned here).
<br><br>

<strong>Precautions:</strong> Acute haemorrhoidal attack- if the haemorrhoid symptoms do not disappear within 15 days, consult your doctor for advice.
Venous circulation disorders- the most effective way of giving this treatment is in combination with a healthy lifestyle. Avoid exposure to the sun, heat, excessive standing and being overweight. Walking and wearing special support stockings stimulate blood circulation.
If there is any doubt, ask the physician for advice. <br><br>

<strong>Dosage & admin:</strong> The tablets should be taken at meal times.
Venous insufficiency- 2 tablets daily, one at
midday and one in the evening.
Acute haemorrhoidal attack- a 4-day course of
6 tablets daily, followed by 4 tablets daily over
the next 3 days.<br><br>

<strong>Drug Inter:</strong> If the patient is under any other
treatment or needs other treatmant, consult the
physician regarding the medicine, whether there
is any chanch of drug interaction.<br><br>

<strong>Pregnancy & lactation:</strong> Consult the physician
before the desired pregnancy. In the absence of
data on breast milk, breast feeding shoud be
avoided during treatment.
In general, if one is pregnant or on breast-
feeding, she should always ask her physician for
advice before using a medication. <br><br>

30's pack: 363.00 MRP  </p>
        </div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Parenteral anticoagulants" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Parenteral anticoagulants  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> HEPARIN  </h3>
          <p>  HEPARIN: Injection
Heparin sodium 1000 units, 5000 units & 25000 units per 1 ml ampoule<br><br>

<strong>Ind:</strong> Treatment & prophylaxis against deep-vein thrombosis & pulmonary embolism; disseminated intravascular coagulation (DIC); prevention of post operative thrombosis; unstable angina & acute peripheral arterial occlusion; myocardial infarction.<br><br>

<strong>C/I:</strong> Haemophilia and other haemorrhagic conditions, thrombocytopenia, peptic ulcer, recent cerebral haemorrhage, severe hypertension, severe liver disease (including oesophageal varices), renal failure, after major trauma or recent surgery; hypersensitivity to heparin.
<br><br>

<strong>S/E:</strong> Haemorrhage, skin necrosis, thrombocytopenia, hypersensitivity reactions (including urticaria, angioedema, & anaphylaxis); osteoporosis after prolonged use, and rarely alopecia.<br><br>

<strong>Cautions:</strong> Concurrent admn. of oral anticoagulants, dextran inj. or drugs affecting platelet function; pregnancy; thrombocytopenia- usually develops after 6 to 10 days of heparin use, so incase of patients receiving heparin for longer than 5 days, if any develops thrombocytopenia- stop heparin immediately. In these cases alternative therapy with low molecular weight heparin or oral anticoagulant may be given. <br><br>

<strong>Dosage:</strong> Treatment of deep-vein thrombosis and pulmonary embolism: adult, by i.v injection, loading dose of 5000 units (10,000 units in severe pulmonary embolism) followed by continuous infusion of 1000-2000 units/hour, or by subcutaneous injection of 15,000 units every 12 hourly under laboratory monitoring. Prophylaxis of deep vein thrombosis: 5000 units 2 hour before surgery then every 8-12 hours until patient is ambulant; in pregnancy, 10,000 units every 12 hourly (with monitoring). Child: lower loading dose, then 15-25 units/kg/hour by i.v infusion or 250 units/kg every 12 hours by s.c injection.
Unstable angina & acute peripheral arterial occlusion: intravenous treatment regimen as for deep-vein thrombosis and pulmonary embolism (above).
Prophylaxis in general surgery: By s.c injection 5000 units 2 hours before surgery, then every 8-12 hours for 7 days or until patient is anbulant (monitoring not needed); during pregnancy (with monitoring), 5000-10,000 units every 12 hours.<br><br>

<strong>Myocardial infarction:</strong> For the prevention of coronary re-occlusion after thrombolysis, heparin is used in a variety of regimens according to locally agreed protocols. Prevention of mural thrombosis: Heparin is considered effective when given by s.c injection of 12,500 units every 12 hours for at least 10 days.  </p>
        </div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>HEPARIN-Rotex Inj. Rotex Medica/City Overseas</h3>
    <p>Heparin sodium 5000 i.u/ml: injection 5ml vial x l's pack: 135.00 TP</p>   
</div><!-- collapsible -->
              

      </div><!-- collapsible-set -->


        <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  ENOXAPARIN </h3>
          <p>ENOXAPARIN: Injection<br><br>
Enoxaperin is a low molecular weight heparin, available as enoxaparin sodium 20mg (2000 IU)/0.2ml, 40mg (4000 IU)/0.4ml, 60mg (6000 IU)/0.6ml & 80mg (8000 IU)/0.8ml contained in ready-to-use prefilled syringe: for s.c injection. Ind: i. Prophylaxis of venous thromboembolic diseases (prevention of blood clot formation in the veins) in particular after certain procedures, ii. prevention of thrombus formation in the extra corporal circulation during haemodialysis. <br><br>

<strong>C/I;S/E;Cautions:</strong> See under heparin. Do not inject intramuscularly.<br><br>

<strong>Dosage & Admin:</strong> Prophylaxis of deep vein thrombosis, by s.c injection (in the subcutaneous celluler tissue of the anterolateral or posterolateral abdominal wall, alternatively between the left and right sides), moderate risk, 20mg 1-2 hours before surgery then 20mg every 24 hours for 7-10 days; high risk, 40mg 12 hours before surgery then 40mg every 24 hours for 7-10 days.In general surgery, the first injection should be given 2 hours before the surgical procedure; in orthopaedic surgery, the first injection is to be given 12 hours preoperatively.Enoxaparin therapy is usually prescribed for an average period of 7 to 10 days; longer treatment duration may be appropriate in certain cases and the treatment should be continued for as long as there is a risk of venous thrombo-embolism and until the patient is ambulatory.<br><br>

Prevention of extra corporeal thrombus during haemodialysis: The recommended dose is 1mg/kg. Enoxaparin should be introduced in the arterial line of the circuit at the beginning of the dialysis session. The effect of this dose is usually sufficient for a 4-hour session; in the event, if fibrin rings are found, a further dose of 0.5-1mg/kg may be given.<br><br>

<strong>Treatment of established deep vein thrombosis:</strong>
A dose of 1mg/kg should be given s.c every 12 hours. The duration of treatment should not exceed a period of 10 days.<br><br>

<strong>Treatment of unstable angina & non-Q-wave myocardial infarction:</strong> A dose of 1mg/kg should be given s.c every 12 hours. The recommended treatment should be prescribed for a period of 2 to 8 days, until clinical stabilization of the patient. Enoxaparin should be administered concurrently with aspirin (100 to 325mg daily per oral route).<br><br>

<strong>Elderly:</strong> No dosage adjustment is necessary in preventive therapy; in curative therapy measurement of anti-Xa activity is recommended.<br><br>
<strong></strong>
<strong>Children:</strong> Enoxaparin in not recommended in children.
Renal impairment: No dosage adjustment is necessary at prophylactic doses, whereas dosage adjustment is necessary and the monitoring of anti-Xa activity is recommended at curative doses.
Patients under 40kg and over 100kg weight:
Particular clinical surveillence is necessary in order to adjust dosage if necessary. Management of overdose: Accidental overdosage after s.c injection of massive doses of enoxaparin could lead to bleeding complications. Neutralization can be obtained by slow i.v injection of protamine (1mg protmaine can be used to neutralize the anticoagulant effect of 1mg of enoxaparin). Drug inter: In order to avoid possible interactions not recommended combinations (substances increasing the risk of haemorrhage)- acetylsalicylic acid (and derivatives) at analgesic and antipyretic doses, NSAIDs (general route), ticlopidine, dextran 40 (parenteral use). Combinations to be used with caution- oral anticoagulant, thrombolytic drugs, acetylsalicylic acid at anticoagulant platelet doses (in the treatment of unstable angina & non-Q-wave myocardial infarc-tion), glucocorticoids (general route).
</p>
        </div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARDINEX Inj. Drug Inter.</h3>
    <p>Enoxaperin sodium 40mg 
    (4000 IU)/ampoule, 60mg (6000 IU)/ampoule & 80mg (8000 IU)/ampoule: 
    for s.c injection.<br>
    40mg (or 4000 IU) ampoule: 325.00 MRP 60mg (or 6000 IU) <br>
    ampoule: 475.00 MRP 80mg (or 8000 IU) ampoule: 525.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLEXANE Inj. Sanofi Aventis</h3>
    <p>Enoxaperin sodium 20mg (2000 IU)/0.2ml, 40mg (4000 IU)/0.4ml, 60mg (6000 IU)/0.6ml & 80mg (8000 IU)/0.8ml contained in ready-to-use prefilled syringe. It is a low molecular weight heparin.<br><br>
0.2m1 (20mg or 2000 IU) prefilled syringe: 425.06 MRP<br>
0.4ml (40mg or 4000 IU) prefilled syringe: 743.06 MRP<br>
0.6ml (60mg or 6000 IU) prefilled syringe: 1049.52 MRP<br>
0.8ml (80mg or 8000 IU) prefilled syringe: 1343.38 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PARINOX Inj. Incepta</h3>
    <p>Enoxaperin sodium 20mg (2000 IU)/ampoule, 40mg (4000 IU)/ampoule, 60mg (6000 IU)/ampoule & 80mg (8000 IU)/ampoule: for s.c injection.
20mg (or 2000 IU) ampoule: 175.00 MRP <br>
40mg (or 4000 IU) ampoule: 325.00 MRP <br>
60mg (or 6000 IU) ampoule: 475.00 MRP <br>
80mg (or 8000 IU) ampoule: 525.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Oral anticoagulants" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Oral anticoagulants  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>WARFARIN</h3>
          <p>  WARFARIN: Tablet<br><br>
Warfarin sodium is an anticoagulant that acts by inhibiting the synthesis of vitamin K dependent cloting factors, viz. Factors II, VII, IX and X. Anticoagulant effect generally occurs within 24 hours after drug administration. This reaches a maximum in 36-48 hours and is maintained for 48 hours or more after administration is stopped. Warfarin sodium is widely used than others due to less allergic side-effects.<br><br>

<strong>Ind:</strong> prophylaxis of embolisation in rheumatic heart disease and atrial fibrillation; prophylaxis after insertion of prosthetic heart valve; prophylaxis and treatment of venous thrombosis and pulmonary embolism; transient ischaemic attacks.<br><br>

<strong>C/I:</strong> Actual or potential haemorrhagic conditions e.g peptic ulcer; severe hypertension; severe hepatic or renal disease; pregnancy; known hypersensitivity to warfarin; bacterial endocarditis Its use within 24 hours following surgery or labour should be undertaken with caution, it at all.
<br><br>

<strong>S/E:</strong> Haemorrhage is the principal adverse effect of oral anticoagulants. Other adverse reactions include nausea, vomiting, diarrhoea, hypersensitivity, rash, alopecia, and unexplained drop in haematocrit, 'purple toes', skin necrosis, jaundice, and hepatic dysfunction.
Cautions & Warnings: Hepatic or renal disease, recent surgery.
Periodic determination of prothrombin time (PT)/international normalized ratio (INR) or other suitable coagulation test is essential. It is
generally good practice to monitor the patient's response with additional PT/INR determination in
the period immediately after discharge from the hospital and whenever other medications are initiated, discontinued or taken irregularly. Careful additional laboratory control is necessary if the patient is to be changed from one formulation to another. Reversal of warfarin anticoagulation by vitamin K takes several days. In emergency situations fresh frozen plasma should be given.<br><br>

<strong>Pregnancy & lactation:</strong> Warfarin is contraindicated in the first trimester of pregnancy because of the risk of teratogenicity. It should not be used in women who are or may become pregnant because the drug passes through the placental barrier and may cause fatal haemorrhage to the foetus. Warfarin appears in the milk of nursing mothers in an inactive form. Infants nursed by mothers treated with warfarin had no change in prothrombin times. Effects in premature infants have not been evaluated.<br><br>

<strong>Dosage & admin:</strong> The base-line prothrombin time should be determined before the initial dose of warfarin is given, whenever is possible. The usual adult induction dose of warfarin is 10mg daily for 2 days. The initial dose should be reduced if base-line prothrombin time is prolonged, the liver-function tests are
abnormal or if the patient is in cardiac failure, is on parenteral feeding less than average body weight, or over 80 years of age.
The subsequent maintenance dose must depend upon the prothrombin time and is usually 3- 9mg daily and should be taken at the same time each day. The mainte-nance dose is omitted if the prothrombin time is excessively prolonged. Once the maintenance dose is established in the therapeutic range, it is rarely necessary to alter. In emergencies, anticoagulant therapy should be initiated with heparin and warfarin together. Where there is less urgency, as in patients disposed to or at special risk of thromboembolism, anticoagulant therapy may be initiated with warfarin alone. Control tests must be made at regular intervals and maintenance dosage should be adjusted every time according to the results obtained. Use in children: Safety and efficacy in children less than 18 years old have not been established. However, there
is evidence of use and the initial dose in usually 0.1mg/kg/day adjusted subsequently to aim for an INR (international normalized ratio) range the same as in adults.<br><br>

<strong>Drug Inger:</strong> Oral anticoagulants have a greater potential for clinically significant drug interactions. Warn all patients about potential hazards and instruct against taking any drug, including non-prescription products, without the advice of a physician.
Overdosage: If haemorrhage occurs or a potential bleeding state arises, excessive depression of the coagulation activity can be corrected by temporary withdrawal of warfarin accompanied, if necessary, by infusion of fresh-frozen plasma or whole blood. Vitamin K, 5 to 10mg orally or intravenously, may be required to supplement specific treatment with factor concentrates. Pharmaceutical precautions: Replace cap
securely and protect from light  </p>
        </div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>FAREVAN Tab. Gaco</h3>
    <p>Warfarin sodium 5mg/tablet 100's pack: 303.43 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>WARIN Tab. Incepta</h3>
    <p>Warfarin sodium 5mg/tablet 100's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Aspirin" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Aspirin   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  ASPIRIN: Tablet </h3>
          <p>  Aspirin (or acetyl salicylic acid) is a potent analgesic, antipyretic & anti-inflammatory drug belonging to the NSAID group. It also has got antiplatelet & antithrombotic action & hence used in the treatment of coronary & cerebrovascular diseases.<br><br>
<strong>Mode of action:</strong> The antithrombotic action of aspirin is mediated through inhibition of platelet activation. Aspirin acts by causing irreversible inhibition of the cyclooxygenase (COX-1) enzyme, which is responsible for the formation of thromboxane A2 from arachidonic acid and this thromboxane A2 is ultimately
responsible for platelet aggregation through a series of reactions.<br><br>

<strong>Ind:</strong> Prophylaxis of cerebrovascular disease or myocardial infarction; to reduce the risk of myocardial infarction in patients who have had a previous attack or in patients with unstable angina. Prevention of graft occlusion following aortocoronary by-pass surgery.<br><br>

<strong>C/I:</strong> Children under 12 years (unless specially indicated) and in breast feeding mother, active peptic ulceration, haemophilia and other bleeding disorders. Aspirin should not be given to patients with asthma.<br><br>

<strong>S/E:</strong> Side-effects are mild for usual dosage of aspirin. These are nausea, dyspepsia, gastrointestinal ulceration & bronchospasm. Aspirin may induce gastric irritation and gastrointestinal haemorrtage. There may be skin reactions in hypersensitive patients. Prolonged administration may give rise to hearing disturbances, such as tinnitus.<br><br>

<strong>Precautios:</strong> Aspirin should be administered cautiously in uncontrolled blood pressure & in patients with history of brochospasm or asthma (if clearly needed); impaired renal or hepatic function; dyspepsia & dehydration.
It should be given with caution to patients with nasal polyps and nasal allergy.<br><br>

<strong>Pregnancy & Lactation:</strong> It is evident that aspirin is safe in pregnancy, but it may prolong labour and contribute to maternal and neonatal bleeding and is best avoided in the last trimester of pregnancy unless recommended by the physician. Aspirin is excreted in low concentration in breast milk, but is unlikely to cause adverse effect to the breast-fed infant.<br><br>

<strong>Dosage & Admin:</strong> Thrombotic cerebrovascular or cardiovascular disease: 75mg tablet 1 to 4 daily. Myocardial infarction: 75mg tablet 1 to 2
daily. Followig by-pass surgery: 75mg tablet
daily or as directed by the physician.<br><br>

<strong>Children</strong>- not to be given to children under 12 years, unless the expected benefits outweigh the possible risks.<br><br>

<strong>Drug Inter:</strong> Aspirin may enhance the effects of anticoagulants, oral hypoglycaemics and methotrexate and decreases the action of uricosuric drugs.  </p>
        </div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ACIPRIN CV Tab. ACI</h3>
    <p>Aspirin 75mg/tablet (e.c) 100's pack: 38.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGIN Tab. Pharmadesh</h3>
    <p>Aspirin 75mg/tablet 100's pack: 37.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGIPRIN-75 Tab. Rephco</h3>
    <p>Aspirin 75mg/tablet (e.c) 100's pack: 37.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>A.S.A-CV Tab. Apex</h3>
    <p>Aspirin 75mg/tablet 100's pack: 37.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAID Tab. Jayson Aspirin</h3>
    <p>75mg & 100mg/tablet (enteric coated) 75mg x 50's pack: 18.50 MRP
100mg x 100's pack: 28.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARDOPRIN Tab. Jalalabad</h3>
    <p>Acetylsalicylic acid 75mg/tablet (enteric coated) 100's pack: 37.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARDOPYRIN Tab. Gaco</h3>
    <p>Acetylsalicylic acid 75mg/tablet
100's pack: 37.10 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARDOPYRIN-EC Tab. Gaco</h3>
    <p>Acetylsalicylic acid 75mg/tablet (enteric coated) 100's pack: 41.08 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CARVA Tab. Square</h3>
    <p>Acetylsalicylic acid 75mg/tablet (enteric coated) 100's pack: 37.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DISPRIN CV 100 Reckitt Benckiser</h3>
    <p>Aspirin 100mg/tablet (e.c) for cardiovascular use. 10,000's pack: 2520.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ECOSPRIN Tab. Acme</h3>
    <p>Aspirin 75mg/tablet (enteric coated) 75mg x 100's pack: 50.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ENCOPRIN L.D Tab. Medimet</h3>
    <p>Aspirin 75mg/tablet (low dose). 100's pack: 37.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ERAS-75 Tab. UniHealth</h3>
    <p>Aspirin 75mg/tablet (e.c)
75mg x 100's pack: 37.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>G-ASPIRIN Tab. Gonoshas.</h3>
    <p>Aspirin 100mg/tablet (e.c) 100's pack: 32.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MONOSPRIN Tab. Ziska</h3>
    <p>Aspirin 75mg/tablet (e.c)
100's pack: 37.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NEOSPIN Tab. Edruc</h3>
    <p>Aspirin 75mg/tablet (e.c)
75mg x 100's pack: 37.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SOLRIN Tab. Opsonin</h3>
    <p>Aspirin 75mg/tablet
75mg x 100's pack: 50.00 MRP</p>   
</div><!-- collapsible -->


              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="CLOPIDOGREL" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> CLOPIDOGREL   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CLOPIDOGREL: Tablet  </h3>
          <p>  Clopidogrel is a thienopyridine derivative, and is effective as an antiplatelet agent. It is available as tablet of clopidogrel bisulphate INN 97.88mg equivalent to clopidogrel 75mg.<br><br>

<strong>Mode of action:</strong> Clopidogrel is an inhibitor of platelet aggregation. It acts by interfering with the platelet activation cascade. It blocks the activation of platelets by adenosine diphosphate (ADP) receptor selectively and irreversibly inhibiting the binding of the glycoprotein GP IIb-IIIa complex, the major receptor for fibrinogen present in the platelet surface. Clopidogrel may antagonize the ADP induced inhibition of adenylate cyclase possibly resulting in an elevated platelet cyclic adenosine monophosphate level after stimulation by an appropriate agonist. Ind: Clopidogrel is used for the reduction of atherosclerotic events in patients with atherosclerosis documented by recent stroke, recent myocardial infarction or with established peripheral arterial disease. The major indications are- stroke, myocardial infarction, peripheral vascular diseases. <br><br>

<strong>C/I:</strong> Known case of hypersensitivity to the drug; active pathological bleeding such as peptic ulcer or intracranial haemorrhage.<br><br>

<strong>S/E:</strong> Very rarely hypersensitivity reactions, such as- angioedema, bronchospasm and anaphylactic reactions. The clinical adverse reactions are as gastro- intestinal haemorrhage, agranulocytosis, dyspepsia, gastritis, diarrhoea, rash, palpitation and vomiting. Precautions: Clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological onditions.<br><br>

<strong>Pregnancy & lactation:</strong> No adequate and well- controlled studies have been done in pregnant & lactating women. Hence, during pregnancy, clopidogrel is only used if it is clearly needed &
in lactation, usually not recommended.<br><br>

<strong>Dosage & admin:</strong> 75mg once daily with or
without food. No dosage administration adjustment is necessary for elderly patients or patients with renal disease.<br><br>

<strong>Children:</strong> Not recommended.<br><br>

<strong>Drug inter:</strong> Aspirin does not modify the clopidogrel mediated inhibition of ADP-induced platelet aggregation. Concomitant administration of clopidogrel with NSAIDs such as naproxen is associated with gastro-intestinal blood loss. No clinically significant interactions have been observed when clopidogrel is co-administered with atenolol, nifedipine or both atenolol and nifedipine.  </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANCLOG Tab. Square</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANLET-75 Tab. Globe</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLAVIX Tab. Techno Drugs</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOGNIL Tab. Orion</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
20's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLONT Tab. Opsonin</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOPID Tab. Drug Inter.</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
50's pack: 600.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOPIDOL Tab. Alco Pharma</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOPILET Tab. Sun Pharma</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOREL Tab. ACI</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet 10's pack: 100.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOTINIL Tab. Rephco</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DCLOT Tab. Acme</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DOREL Tab. General</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FREE Tab. Nipa</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet 20's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIREL 75 Tab. Silva</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet 20's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIVOCARD Tab. White Horse</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOPIREL Tab. Incepta</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NOCLOG Tab. SK+F</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
20's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ODREL Tab. Beximco</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
10's pack: 100.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PLADEX Tab. UniHealth</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet
30's pack: 360.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PLAGRIN Tab. Renata</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet (film coated). 10's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PLAVIX Tab. Navana</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet (film coated). 20's pack: 160.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PRECLOT Tab. Popular</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet (film coated). 20's pack: 200.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>REPLET Tab. Healthcare</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet (film coated). 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="CLOPIDOGREL + ASPIRIN" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  CLOPIDOGREL + ASPIRIN  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  CLOPIDOGREL + ASPIRIN: Tablet </h3>
          <p>  This is a fixed-dose combination formula comprising clopidogrel and aspirin; both are acting as antiplatelet agent. The preparation is available as film-coated tablet, each containing clopidogrel bisulphate INN 97.88mg equivalent to clopidogrel 75mg and aspirin BP 75mg<br><br>

<strong>Mode of action:</strong> See under the text of clopidogrel and aspirin separately.<br><br>

<strong>Ind:</strong> This combined preparation is indicated for the reduction of thrombotic events as in: i. Recent MI, recent stroke or established peripheral arterial disease; ii. Acute coronary syndrome (unstable angina/non-Q-wave MI).<br><br>

<strong>C/I:</strong> Hypersensitivity to clopidogrel or aspirin or any NSAID. Recent history of gastrointes-tinal bleeding. Active pathological bleeding such as peptic ulcer or intracranial hemorrhage, or bleeding disorders like hemophilia.<br><br>

<strong>S/E:</strong> The drug is generally well tolerated. Side effects that have been reported are- abdominal pain, dyspepsia, gastritis, diarrhea, nausea, vomiting, constipation, gastrointestinal hemorrhage, ulceration, neutropenia, rash, palpitation, syncope, drowsiness, asthenia, neuralgia, paresthesia and vertigo.<br><br>

<strong>Precautions: General:</strong> As with other anti-platelet agents, this combination drug should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or other pathological conditions. If patient is to undergo elective surgery and an anti-platelet effect is not desired, this drug should be discontinued 7 days prior to surgery.
GI bleeding: The combination of clopidogrel and aspirin prolongs the bleeding time. So, it should be used with caution in patients who have lesions with a propensity to bleed (such as ulcers). Thrombotic thrombocytopenic purpura (TTP): TTP has been reportedrarely following use of
clopidogrel.<br><br>

<strong>Reye's syndrome:</strong> Reye's syndrome may develop in individuals who have chicken pox, influenza or flu symptoms. This combination is not recommended for use in patients with chicken pox, influenza or flu symptoms.<br><br>

<strong>Nasal polyps or nasal allergies:</strong> The combination drug of clopidogrel and aspirin should be administered with caution in patients with nasal polyps or nasal allergies.
Hepatic or renal impairment: This should be avoided in patients with impaired hepatic and renal function. Aspirin causes sodium and water retention in patients with renal impairment and increases the risk of gastrointestinal bleeding.<br><br>

 <strong>Pregnancy & lactation:</strong> Asdverse effects are increased in the mother and the fetus following chronic ingestion of aspirin. Because of possible adverse effects on the neonate and the potential for increased maternal blood loss, this combination should be avoided during the last three months of pregnancy. This product should also be avoided in nursing mothers because of the possible risk of developing Reye's syndrome. Regular use of high doses of aspirin could impair platelet function and produce hypoprothrombinemia in infants if neonatal vitamin K levels are low.<br><br>

<strong>Dosage & admin:</strong> Recent MI, recent stroke, or established peripheral arterial disease: The recommended daily dose of this combined preparation (75mg + 75mg) is one tablet daily. Acute coronary syndrome: In acute coronary syndrome (unstable angina/non-Q-wave MI), the dose should be initiated with a 4 tablet stat loading dose and then continued at one tablet daily.  </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANCLOG Plus Tab. Square</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 30's pack: 330.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANLET Plus Tab. Globe</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (film- coated). 30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ASPIN Plus Tab. Aristopharma</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 30's pack: 330.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLAS Tab. Delta</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 10's pack: 110.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOGNIL Plus Tab. Orion</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 20's pack: 220.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLONTAS Tab. Opsonin</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 30's pack: 330.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOPID-As Tab. Drug Inter.</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 50's pack: 600.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOPIDOL PLUS Tab. Alco Pharma</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c) 20's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOREL-A Tab. ACI</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 30's pack: 330.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>COMBIPLAT Tab. Beacon</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 30's pack: 330.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DOREL Plus Tab. General</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 20's pack: 220.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ECOSPRIN Plus Tab. Acme</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 20's pack: 220.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIVOCARD Plus Tab. White Horse</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 30's pack: 330.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOPIREL Plus Tab. Incepta</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 20's pack: 220.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ODREL Plus Tab. Beximco</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 30's pack: 330.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PLADEX-A Tab. UniHealth</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 30's pack: 375.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PLAGRINPLUS Tab. Renata</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 20's pack: 220.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PLAVIX Plus Tab. Navana</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 20's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PRECLOT AS Tab. Popular</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 30's pack: 330.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ZESPRIN Tab. Zenith</h3>
    <p>Clopidogrel bisulphate INN equivalent to clopidogrel 75mg & aspirin BP 75mg/tablet (f.c). 50's pack: 500.00 MRP</p>   
</div><!-- collapsible -->
     

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="FIBRINOLYTIC DRUGS" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>FIBRINOLYTIC DRUGS</h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>STREPTOKINASE</h3>
          <p>  STREPTOKINASE: Injection<br><br>

<strong>Ind:</strong> Deep-vein thrombosis, pulmonary embolism, acute arterial thromboem-bolism, thrombosed arteriovenous shunts; acute myocardial infarction. <br><br>

<strong>C/I:</strong> Recent haemorrhage, trauma, or surgery (including dental extraction), coagulation defects, bleeding diatheses, history of cerebrovascular disease specially recent events or with any residual disability, recent symptoms of possible peptic ulceration, heavy vaginal bleeding, severe hypertension, pulmonary disease with cavitation, acute pancreatitis, diabetic retinopathy, severe liver disease, oesophageal varices. In the case of streptokinase previous allergic reactions to drug, or therapy with the drug from 5 days to 12 months previously.<br><br>

<strong>S/E:</strong> Side-effects are mainly mausea and vomiting and bleeding. Back pain has been reported. Bleeding is usually limited to the site of infection, but intracerebral haemorrhage or bleeding from other sites may occur. Serious bleeding calls for discontinuation of the drug and may require administration of coagulation factors and antifibrinolytic drugs (aprotinin or tranexamic acid). Streptokinase may cause allergic reactions and anaphylaxis has been reported.
<br><br>

<strong>Cautions:</strong> risk of bleeding from venepuncture or invasive procedures, any external chest compression, pregnancy, possibility of pre- existing thrombus as in abdominal aneurysm or enlarged left atrium with atrial fibrillation (risk of dissolution of clot and subsequent embolisation), recent or concurrent anticoagulant therapy.<br><br>

<strong>Dose:</strong> by intravenous infusion, 250,000 units over 30 minutes, then 100,000 units every hour for up to 24-72 hours according to condition. Myocardial infarction, 1500,000 units over 60 minutes followed by aspirin 150mg daily by mouth for at least 4 weeks.  </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>DURAKINASE Inj. Dong Kook/Hyeimpex</h3>
    <p>Streptokinase powder (for reconstitution), 1.5 million unit/vial: Injection.
1.5 million unit vial: 2416.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>STREPTASE Inj. Sanofi Aventis</h3>
    <p>Streptokinase powder (for reconstitution), 1.5 million unit/vial: Injection.
1.5 million unit vial: 3100.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Antifibrinolytic & haemostatic drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Antifibrinolytic & haemostatic drugs   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">



<div data-role="collapsible"> <!-- collapsible -->
      <h3> ADRENOCHROME MONOSEMICARBAZONE  </h3>
          <p>    </p>
      </div><!-- collapsible -->

      <div data-role="collapsible"> <!-- collapsible -->
          <h3>ANAROXYL Tab. Nuvista</h3>
          <p>Adrenochrome monosemicarbazone 2.5mg/tablet Ind: Haemorrhagic disorder.
      Dose: Orally, 1-2 tablets 3 times daily.
      30's pack: 414.00 MRP</p>   
      </div><!-- collapsible -->

      <div data-role="collapsible"> <!-- collapsible -->
          <h3>ANAROXYL Inj. Nuvista</h3>
          <p>Adrenochrome monosemicarbazone 5mg/1ml ampoule: injection.
      Ind: Haemorrhagic disorder.Dose: By i.m. injection 1 amp. once to thrice daily, for medical haemorrhage.
      5 amps.pack: 247.50 MRP</p>   
      </div><!-- collapsible -->
              

</div><!-- collapsible-set -->




<div data-role="collapsible-set" data-theme="a">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  AMINOCAPROIC ACID </h3>
          <p>  It is an effective antifibrinolytic haemostatic agent.<br><br>

          <strong>Ind:</strong> All haemorrhagic syndromes due to enhanced fibrinolysis; postpartum & other obstetric haemorrhages with hyperfibrinolytic pathogenesis; haemorrhages after prostate,cardiac, pulmonary & other surgical procedures & haemophilia & dental extraction.
          <br><br>

          <strong>C/I:</strong> Thromboembolic diseases, arterial & venous thrombosis; early pregnancy.<br><br>

          <strong>S/E:</strong> Fatigue, conjunctival occlusion, pruritus, skin rashes. After oral admin.- nausea, diarrhoea, dizziness; if hypersensitization, avoid or stop treatment.<br><br>

          <strong>Cautions:</strong> Renal impairment; it is advisable to avoid in pregnancy (as
          transplacental transit occurs) particularly in first & 2nd trimester.<br><br>

         <strong> Dose:</strong> usual dose is 4-5 gm initially i.v. (or orally) followed by 1.25 gm/ hour until bleeding is controlled. The total dose should not exceed 30gm in 24 hours. The average dose is 8-16 gm a day & is to be given as 1-2 maps. 6 hourly. Rapid i.v. admin. should be avoided to prevent hypotension,, bradycardia & other
          arrhythmias.  </p>
        </div><!-- collapsible -->



        <div data-role="collapsible"> <!-- collapsible -->
            <h3>CAPROLEX Inj. Techno Drugs</h3>
            <p>Aminocaproic acid 1gm in 5m1 & 2gm in 10ml ampoule: injection 5m1 (1gm) amp x 5's pack: 72.50 MRP 10m1 (2gm) amp x 5's pack: 130.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>CAPROLISIN Inj. Malesci/Pacific Pharma</h3>
            <p>Aminocaproic acid 2gm in 10ml ampoule: injection 10 amps. pack: 500.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>HEMOSIN Inj. Chemist</h3>
            <p>Aminocaproic acid 1gm in 5m1 ampoule: injection 10 amps pack: 151.00 MRP</p>   
        </div><!-- collapsible -->

</div><!-- collapsible-set -->



<div data-role="collapsible-set" data-theme="b">

      <div data-role="collapsible"> <!-- collapsible -->
      <h3>  PHYTOMENADIONE </h3>
      <p><strong>PHYTOMENADIONE:</strong> Tablet/ Injection <br><br>

      <strong>Ind:</strong> hypoprothrombinaemia; prophylaxis & treatment of haemorrhagic diseases of the newborn (synthetic analogues of vita-k, should be avoided in newborn because of the risk of kernicterus).<br><br>
      
      <strong>Caution:</strong> anaphylactoid reactions may occur with parenteral administration.<br><br>
      
     <strong> Dose: Orally- adult</strong>, 10-20mg, max. 40mg in 24 hours. Child- neonates, 1mg; over 3 months, 5- 10mg.<br><br>
      
      <strong>By injection- adult</strong>, 10-20mg i.m or slow i.v, max. 40mg in 24 hours.<br><br>
      
      <strong>Child:</strong> neonates, 1mg i.m; over 3 months, 5-10mg.</p>
      </div><!-- collapsible -->

    <div data-role="collapsible"> <!-- collapsible -->
        <h3>BABYKION Oral/I.M/I.V Inj. Chemist</h3>
        <p>Phytomenadione 2mg per 0.2 ml ampoule: injection 2mg amp x 5's pack: 375.00 MRP</p>   
    </div><!-- collapsible -->

    <div data-role="collapsible"> <!-- collapsible -->
        <h3>KONAKION MM Inj. Roche</h3>
        <p>Phytomenadione 2mg per 0.2 ml ampoule & 10mg per 1ml ampoule: injection 2mg amp x 5's pack: 393.75 MRP 10mg amp x 5's pack: 421.88 MRP</p>   
    </div><!-- collapsible -->
              

</div><!-- collapsible-set -->



<div data-role="collapsible-set" data-theme="e">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>TRANEXAMIC ACID   </h3>
          <p> <strong>TRANEXAMIC ACID:</strong> Capsule/ Injection Ind: it acts by inhibiting plasminogen activation & fibrinolysis, and useful in haemorrhage in prostatectomy, dental extraction in haemophiliacs or menorrhagia; also used in hereditary
        angioedema & in streptokinase overdose.<br><br>

        <strong>C/I:</strong> thromboembolic disease.<br><br>
        
        <strong>S/E:</strong> nausea, vomiting, diarrhoea (reduce dose); giddiness on rapid intravenous injection. Cautions: reduce dose in renal impairment; massive haematuria (avoid if risk of ureteric obstruction); regular eye examination and liver function tests in long-term treatment of hereditary angioedema.<br><br>

        <strong>Dose:</strong> orally, 1-1.5gm 2-4 times daily.
        By slow intravenous injection, 0.5-1gm 3 times daily.   </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>AZEPTIL Cap. Tablets (India)/ Hyeimpex</h3>
            <p>Tranexamic acid 250mg & 500mg/capsule.
        250mg x 20's pack: 129.80 MRP 500mg x 20's pack: 228.21 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TRACID Tab. Acme</h3>
            <p>Tranexamic acid 500mg/tablet. 30's pack: 450.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TRACID Inj. Acme</h3>
            <p>Tranexamic acid 500mg/5ml ampoule: slow i.v injection
        3 amps pack: 150.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TRAMIC Cap. Pacific</h3>
            <p>Tranexamic acid 500mg/capsule. 30's pack: 570.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TRANEX Inj. Malesci/Pacific</h3>
            <p>Tranexamic acid 500mg/5ml ampoule: slow i.v injection 6 amps pack: 287.10 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TRAXYL Cap. Nuvista</h3>
            <p>Tranexamic acid 500mg/capsule. 500mg x 20's pack: 320.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TRAXYL Inj. Nuvista</h3>
            <p>Tranexamic acid 250mg/5ml ampoule:injection
        5 amps pack: 150.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TREXAM Cap. Healthcare</h3>
            <p>Tranexamic acid 500mg/capsule. 30's pack: 390.00 MRP</p>   
        </div><!-- collapsible -->   

</div><!-- collapsible-set -->




<div data-role="collapsible-set" data-theme="d">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  ANTIHAEMOPHILIC FACTOR </h3>
          <p><strong>HUMAN ANTIHAEMOPHILIC FACTOR (Factor VIII): Injection</strong>
Human antihaemophilic factor (Factor VIII) is a sterile, lyophilized concentrate preparation, collected from pooled plasma from suitable human donors.
It is supplied as a single dose for intravenous administration.<br><br>

<strong>Ind:</strong> Control of haemorrhage in Haemophilia A; or acquired factor VIII deficiency.<br><br>

<strong>S/E:</strong> Allergic reactions including chills, fever; hyperfibrinogenaemia occurred after massive doses with earlier products but less likely since fibrinogen content has now been substantially reduced.<br><br>

<strong>Cautions:</strong> Intravascular haemolysis after large or frequently repeated doses in patients with blood groups A, B or AB<br><br>

<strong>Dosage & Admin:</strong> This should be administered i.v within three hours after reconstitution with the diluent supplied. It may be administered by injection (plastic syringe only) or drip infusion. Administer at room temperature, do not
refrigerate after reconstitution and discard any unused contents. Dose calculation: The following formula
provides a guide for dosage calculation-
Body wt. (in kg) x 0.40 IU/kg x percent of desired factor VIII increase (%) = required units of antihaemophilic factor.
In paediatric patients, a factor of 0.5 IU/kg can be calculated.
Mild to moderate haemorrhages can usually be treated with a single administration sufficient to raise the plasma Factor VIII level to 20-30%. In the event of more serious haemorrhage, the patient's plasma Factor VIII level should be raised to 30-50%. Infusions are generally required at twice daily intervals over several days.
Surgery in patients with Factor VIII deficiency requires that postoperati-vely, the Factor VIII level be raised to 50-80% and maintained at or above 30%, for approximately two weeks. For dental extractions the Factor VIII level should be raised to 50% immediately prior to the procedure; further antihaemophilic Factor preparation may be given if bleeding occurs.
In patients with severe Factor VIII deficiency who experience frequent haemorrhages, the antihaemophilic Factor preparation may be administered prophylactically on a daily or every other day schedule to raise the Factor VIII level to approximately 15%. Factor VIII levels should be monitored periodically to evaluate individual patient response to the dosage regime. Preparations: As per information, no product is available now in our market, from any registered company.</p>
        </div><!-- collapsible -->



      <div data-role="collapsible"> <!-- collapsible -->
          <h3>ALPHANATE 250 IU Inj. Grifols/Shuvro Ltd.</h3>
          <p>Human antihaemophilic factor or Factor VIII/ VWF (Von Willebrand factor) complex concentrate; double inactivated & highly purified: i.v injection. Factor VIII & VWF naturally go together in the human blood. VWF is the natural carrier molecule of factor VIII. The survival of factor VIII depends on VWF by which it is protected in the plasma; the presence of VWF prevents factor VIII degeneration & creates a prolonged antigen presentation, which could be beneficial in terms of immune tolerance induction.
          Ind: S/E; Cautions: See above under the text. Dosage & admin: See above under the text. 250 I.0 vial: 6569.70 MRP</p>   
      </div><!-- collapsible -->

              

</div><!-- collapsible-set -->
   
    </div><!-- content --> 


    <div data-role="footer" data-position="fixed">
      <h4></h4>
    </div>
    </div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="Ezetimibe" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Ezetimibe   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  EZETIMIBE: Tablet </h3>
          <p>  Ezetimibe INN 10mg/tablet.<br><br>

<strong>Mode of action:</strong> Ezetimibe belongs to a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. Ezetimibe reduces total-C, LDL-C, Apo-B and TG, and increases HDL-C in patients with hypercholesterolemia. Ezetimibe inhibits intestinal cholesterol absorption by about 54%, compared with placebo. Ezetimibe has a mechanism of action different from others. It does not inhibit cholesterol synthesis in the liver, or increase bile acid excretion. Instead, ezetimibe localizes and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the blood circulation and liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the circulation. This distinct mechanism is complementary to that of HMG- CoA reductase inhibitors (viz, statins). As a result, administration of ezetimibe with an HMG-CoA reductase inhibitor is effective in improving serum total-C, LDL-C, Apo-B, TG and HDL-C beyond either treatment alone.<br><br>

<strong>Ind:</strong> Primary hypercholesterolemia (viz: i. Primary heterozygous familial and non-familial hypercholesterolemia, ii. Homozygous familial hypercholesterolemia (HoFH), iii. Homozygous familial sitosterolemia (phytosterolemia)).<br><br>

<strong>C/I:</strong> Hypersensitivity to any component of this medication. The combination of ezetimibe with an HMG-CoA reductase inhibitor (statin) is contraindicated in patients with active liver
disease or unexplained persistent elevations in serum transaminases.
S/E: In clinical trials ezetimibe was found generally well tolerated. The rare side effects include fatigue, abdominal pain, diarrhea, viral infection, pharyngitis, sinusitis, arthralgia, back pain, coughing.<br><br>

<strong>Precautions:</strong> Concurrent administration of ezetimibe with a specific HMG-CoA reductase inhibitor (statin) should be in accordance with the product labeling for that HMG-CoA reductase inhibitor. When ezetimibe is co-administered with an HMG-CoA reductase inhibitor, liver function tests should be performed at initiation of therapy and according to the recommendations of the HMG-CoA reductase inhibitor therapy. Hepatic insufficiency- due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic insufficiency, ezetimibe is not recommended in these patients. Pregnancy & lactation: There are no adequate and well-controlled studies of ezetimibe in pregnant women. Therefore, ezetimibe should be used during pregnancy only if the potential benefit justifies the risk to the fetus.<br><br>

<strong>Dosage & admin:</strong> Before starting treatment with ezetimibe, the patient should be placed on a standard cholesterol-lowering diet and should be continued on this diet during treatment with the drug. The recommended dose of ezetimibe is 10mg once daily. It can be administered with or without food.<br><br>
Treatment with ezetimibe in children (younger than 10 years) is not recommended.
Primary (heterozygous familial and non- familial) hypercholesterolemia:
Ezetimibe monotherapy:
Ezetimibe administered alone, is indicated as adjunct therapy to diet for the reduction of elevated total-C, LDL-C, and Apo-B in patients with primary (heterozygous familial and non- familial) hypercholesterolemia.
Ezetimibe combination therapy with HMG- CoA reductase inhibitors: Ezetimibe, administered in combination with an HMG- CoA reductase inhibitor, is also indicated as adjunct therapy to diet for the reduction of elevated total-C, LDL-C, and Apo-B in patients with primary (heterozygous familial and non- familial) hypercholesterolemia. In case of combination therapy, the daily dose of ezetimibe may be taken at the same time schedule as for the HMG-CoA reductase inhibitor therapy.<br><br>
<strong>Homozygous familial hypercholesterolemia (HoFH):</strong>
Ezetimibe combination therapy with HMG- CoA reductase inhibitors: The combination of ezetimibe and atorvastatin or simvastatin, is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunt to other lipid-lowering treatments (e.g LDL apheresis) or if such treatments are unavailable. In case of combination therapy, the daily dose of ezetimibe may be taken at the same time schedule as for the HMG-CoA reductase inhibitor therapy.
Homozygous familial sitosterolemia<br><br>
(phytosterolemia):
<strong>Monotherapy:</strong> Ezetimibe is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and cmapesterol levels in patients with homozygous familial sitosterolemia.
Patients with hepatic and renal insufficiency: No dosage adjustment is necessary in patients with mild hepatic and renal insufficiency. Elderly patients: No dosage adjustment is necessary in geriatric patients. Co- administration with bile acid sequestrants: Dosing of ezetimibe should occur either 2 hours before or 4 hours after administration of a bile acid sequestrant.
Drug inter: Ezetimbe has no significant effect on a series of porobe drugs (caffeine, dextromethorphan, tolbutamide, and i.v midazolam). This indicates that ezetimibe is neither an inhibitor nor an inducer of these cytochrome P450 isozymes, and it is unlikely that ezetimibe will affect the metabolism of drugs that are metabolized by these enzymes. Concomitant administration of ezetimibe (10mg once daily) had no significant effect on warfarin, digoxin, oral contraceptives, and cimetidine.
HMG-CoA reductase inhibitors: Concomitant administration of ezetimibe (10mg once daily) had no significant effect on the bioavailability of either atorastatin, lovastatin, simvastatin, pravastatin, or fluvastatin.<br><br>
<strong>Fenofibrate:</strong> Fenofibrate (200mg once daily) administration increased the mean Cmax and AUC values of total ezetimibe approximately 64% and 48%, respectively. Pharmacokinetics of fenofibrate was not significantly affected by ezetimibe (10mg once daily).
Cholestyramine: In a study of forty healthy hypercholesterolemic (LDL-C>130mg/dl) adult subjects, concomitant cholestyramine (4gm twice daily) administration decreased the mean AUC values of total ezetimibe and ezetimibe approximately 55% and 80%, respectively.  </p>
        </div><!-- collapsible -->




<div data-role="collapsible"> <!-- collapsible -->
    <h3>CHOLINOR Tab. Square</h3>
    <p>Ezetimibe INN 10mg/tablet. 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EZETA Tab. Beximco</h3>
    <p>Ezetimibe INN 10mg/tablet. 20's pack: 200.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EZETIM Tab. Incepta</h3>
    <p>Ezetimibe INN 10mg/tablet. 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EZETROL Tab. UniHealth/UniMed</h3>
    <p>Ezetimibe INN 10mg/tablet. 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->
              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Fibrates" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Fibrates  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> FENOFIBRATE: Capsule/Tablet  </h3>
          <p>  Fenofibrate is a fibric acid derivative approved for the treatment of hyperlipidemia.<br><br>

<strong>Mode of action:</strong> Fenofibrate is rapidly hydrolyzed after oral ingestion to its pharmacologically active form, fenofibric acid. Fenofibric acid causes reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and VLDL. In addition,
treatment with fenofibrate results in increase in HDL and apo-proteins apoAl apoAll. Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid. Ind: Fenofibrate is indicated for hyperlipidemias of type IIa, IIb, III, IV & V in patients who have not responded adequately to diet & other appropriate measures.<br><br>

<strong>C/I:</strong> Fenofibrate is contraindicated in patients with known hypersensitivity to the drug, severe renal impairment, existing gall bladder disease, hepatic dysfunction including biliary cirrhosis, pregnant women and breast feeding mothers, photosensitivity to ketoprofen.<br><br>

<strong>S/E:</strong> Nausea, anorexia, gastric pain; pruritus, urticaria; impotence; headache, dizziness, vertigo, fatigue, hair loss; myotoxicity.<br><br>

<strong>Precautions:</strong> Special care needed in patients with renal disease, as progressive increases in serum creatinine concentration or failure to follow dosage guidelines may result in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity; discontinue if myotoxicity suspected or creatinine kinase concentration increases significantly. Liver function tests recommended every 3 months for first year.<br><br>

<strong>Pregnancy:</strong> Fenofibrate is not recommended for pregnant women.<br><br>

<strong>Dosage & admin: Adult:</strong> Fenofibrate 200mg one capsule once daily or 67mg 3 capsules daily in divided doses is recommended as the dose for the treatment of primary hypercholesterolemia, hypertriglyceridemia or mixed hyperlipidemia.<br><br>

<strong>Children:</strong> 67mg 1 capsule/20kg body-weight daily.<br><br>
Absorption of fenofibrate is increased by approximately 35% when administered with food.<br><br>

<strong>Drug inter:</strong> Fenofibrate potentiates the anticoagulant effects of warfarin. When administered with antidiabetic drug it may improve glucose tolerance and have additive effect. Fenofibrate may also increase the nephrotoxicity of cyclosporine. Due to a potential increase in the risk of rhabdomyolysis, cautions should be taken against the use of fenofibrate with HMG-CoA reductase inhibitors. However, the use of low-dose statins with fenofibrate appears to be well tolerated.  </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>FENOCAP Cap. Orion</h3>
    <p>Fenofibrate BP 200mg/capsule (micronized). 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FENOCOL Cap. Peoples</h3>
    <p>Fenofibrate BP 200mg/capsule (micronized).
30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FENOLID Cap. General</h3>
    <p>Fenofibrate BP 200mg/capsule. 40's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FENORAT Cap. Pacific</h3>
    <p>Fenofibrate BP 200mg/capsule (micronized). 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FIBRE Cap. White Horse</h3>
    <p>Fenofibrate BP 200mg/capsule (micronized). 50's pack: 350.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPIDOF Cap. Acme</h3>
    <p>Fenofibrate BP 67mg/capsule (micronized). 30's pack: 60.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPIDOF Cap. Acme</h3>
    <p>Fenofibrate BP 200mg/capsule (micronized). 20's pack: 140.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPIRED Cap. Square</h3>
    <p>LIPIRED Cap. Square</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOFAT Cap. Beximco</h3>
    <p>Fenofibrate BP 200mg/capsule (micronized). 30's pack: 210.00 IP 50's pack: 350.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NOFIATE Cap. Incepta</h3>
    <p>Fenofibrate BP 200mg/capsule (micronized). 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TRIGENT Cap. UniHealth</h3>
    <p>Fenofibrate BP 200mg/capsule (micronized). 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Gemfibrozil" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Gemfibrozil  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> GEMFIBROZIL: Capsule  </h3>
          <p>  Ind: Hyperlipidaemias of types Ila, Ilb, III, IV
and V in patients who have not responded adequately to diet and other appropriate measures; primary prevention of coronary heart disease in men aged 40-55 years with hyperlipidaemias that have not responded to diet and other appropriate measures.<br><br>
C/I: Alcoholism, hepatic impairment, gallstones; pregnancy.<br><br>
S/E: Gastro-intestinal disturbances; pruritus, urticaria, rash, headache, dizziness, blurred vision, painful extremities; rarely myalgia; impotence reported.<br><br>
Cautions: Lipid profile, blood counts & liver- function tests before initiating long-term treat- ment; renal impairment; annual eye examinations. Dose: 1.2gm daily, usually in 2 divi ded doses; range 0.9-1.5gm daily.
  </p>
        </div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>DELIPID Cap. Square</h3>
    <p>Gemfibrozil 300mg/capsule 30's pack: 209.40 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FIBRIL Cap. Beximco</h3>
    <p>Gemfibrozil 300mg/capsule 30's pack: 210.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>GELICON Cap. SK+F</h3>
    <p>Gemfibrozil 300mg/capsule 24's pack: 168.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>GEMFIL Cap. Aristopharma</h3>
    <p>Gemfibrozil 300mg/capsule 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="Statins" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Statins  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ATORVASTATIN: Tablet  </h3>
          <p> Atorvastatin, a synthetic lipid-lowering agent. Available as film coated tablet.
<br><br>

<strong>Mode of action:</strong> It is a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyses the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis particularly in the liver. The drug lowers elevated total cholesterol (c), low-density lipoprotein (LDL) cholesterol, apolipoprotein B (apo B), and triglyceride (TG) in patients with primary hypercholesterolaemia and with mixed dyslipidaemia.<br><br>

<strong>Ind:</strong> Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo-B, and TG levels in patients with primary hypercholesterolaemia (heterozygous familial and non-familial) and mixed hyperlipidaemia. Atorvastatin is also indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolaemia as an adjunct to other lipid lowering treatments (eg. LDL apheresis) or if such treatments are unavailable. C/I: The absolute contra-indications to the administration of atorvastatin include active liver disease or unexplained persistent elevations of serum transaminases and hypersensitivity to any component of this medication.<br><br>

<strong>Adverse reactions:</strong> Atorvastatin is well tolerated. Adverse reactions have usually been mild and transient. Less than 2% of patients were discontinued from clinical trials due to side- effects attributed to atorvastatin. The adverse effects that are rarely observed are constipation, flatulence, dyspepsia, abdominal pain, headacle, nausea, myalgia, asthenia, diarrhoea and
insomnia. Atorvastatin can cause elevation in ALT/AST, alkaline phosphatase, GGT, bilirubin and creatine phosphokinse.<br><br>

<strong>Precautions & warnings:</strong> Liver function tests should be performed before the initiation of treatment and periodically thereafter. Patients who develop increased transaminase levels should be monitored until the abnormalities resolve. An increase in ALT or AST >3 times the upper limit of normal, is recommended to reduce the dose or withdraw atorvastatin therapy.
Prior to initiating therapy with atorvastatin, secondary causes for hypercholesterol-aemia (eg. poorly controlled diabetes mellitus, hyothyroidism, nephrotic syndrome, dysproteinaemia, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.
Atorvastatin should be used with caution in patients who consume sustained quantities of alcohol and/or have a history of liver disease. Atorvastatin therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis, eg. severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures.<br><br>

<strong>Pregnancy & lactation:</strong> Cholesterol and other products of cholesterol biosynthesis are essential for foetal development (including synthesis of steroids and cell membranes). Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause foetal harm when administered to pregnant women. Therefore, HMG-CoA reductase inhibitors are contraindicated during pregnancy and in nursing mothers. Atorvastatin should be administered to women of child-bearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking this drug, therapy should be discontinued and the patient appraised of the potential hazard to the foetus.<br><br>

<strong>Dosage & Admin:</strong> Atorvastatin can be administered within the dosage range of 10-80 mg/day as a single daily dose, and can be taken at any time of the day, with or without food. Therapy should be individualized according to the target lipid levels, the recommended goal of therapy, and the patient's response. Primary hypercholesterolaemia and combined byperlipidaemia, usually 10mg once daily. Familial hypercholesterol-aemia, initially 10mg daily, increased at intervals of 4 weeks to 40mg once daily; if necessary, further increased to max, 80mg once daily (or
combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Renal disease has no influence on the plasma concentrations or on the LDL-C reduction of atorvastatin; thus, no adjustment of the dose is required.
Plasma concentrations of atorvastatin are markedly increased in patients with chronic alcoholic liver disease (Childs-Pugh B). The benefits of therapy should be weighed against the risks when atorvastatin is to be given to patients with hepatic insufficiency.<br><br>

<strong>Drug interactions:</strong> Caution should be exercised when atorvastatin is administered with inhibitors of cytochrome P450 3A4 (eg. cyclosporin, macrolide antibiotics including erythromycin and azole antifungals or niacin). Co-administration of an oral antacid suspension containing magnesium and aluminium hydroxide with atorvastatin, decreases atorvastatin plasma concentrations approximately 35%, however, LDL-C reduction usually not altered. Plasma concentration of atorvastatin lowers (approximately 25%) when cholestyramine is co-administered than when either drug is given alone.
Co-administration of multiple doses of atorvastatin and digoxin increased steady-state plasma digoxin concentrations by approximately 20%. Patients taking digoxin should be monitored appropriately.   </p>
        </div><!-- collapsible -->


<div data-role="collapsible"> <!-- collapsible -->
    <h3>GEMFIL Cap. Aristopharma</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP 20mg x 10's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ASTIN Tab. Jayson</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 IP 20mg x 10's pack: 150.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ASTIVA Tab. Supreme</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 10's pack: 100.00 MRP 20mg x 10's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ATASIN Tab. AC!</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 20's pack: 160.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ATOVA Tab. Beximco</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 300.00 IP 20mg x 10's pack: 180.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ATOVIN Tab. Alco Pharma</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 10's pack: 70.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AVAS Tab. Opsonin</h3>
    <p>Atorvastatin 10mg & tablet (f.c) 10mg x 10's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AVASTATIN Tab. Edruc</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 10's pack: 80.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AZTOR Tab. Sun Pharma</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 285.00 MRP 20mg x 30's pack: 540.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>COLOSTAT Tab. Ibn Sina</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP 20mg x 30's pack: 450.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CORD Tab. Hallmark</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 10's pack: 80.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DIVASTIN Tab. Drug Inter.</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPEX-10 Tab. Orion</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 30's pack: 270.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPICON Tab. SK+F</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP
20mg x 10's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPICUT Tab. Rangs Pharma</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP 20mg x 20's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPIGENT Tab. Pacific</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP 20mg x 20's pack: 300.00 MRP +</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPINOR Tab. Rephco</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPITIN Tab. General</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP 20mg x 10's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPLO-10 Tab. Globe</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 10's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPOBI 10 Tab. Nipa</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 20's pack: 80.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIPTOR Tab. Acme</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 20's pack: 160.00 MRP
20mg x 10's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LIVAS Tab. Techno Drugs</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP 20mg x 20's pack: 290.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOCOL Tab. Popular</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 IP
20mg x l's pack: 150.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ORVA Tab. Sanofi Aventis</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP 20mg x 20's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ORVATIN Tab. Chemico</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 20's pack: 160.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>STACOR-10 Tab. UniHealth</h3>
    <p>Atorvastatin 20mg/tablet (f.c) 20mg x 10's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>STACOR-20 Tab. UniHealth</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TAVEN Tab. Renata</h3>
    <p>Atorvastatin 10mg & tablet (f.c) 10mg x 30's pack: 300.00 MRP 20mg x 30's pack: 540.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TCL-R Tab. Aristopharma</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 270.00 MRP 20mg x 10's pack: 170.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TGLOCK Tab. White Horse</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP 20mg x 20's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TIGINOR Tab. Incepta</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP 20mg x 20's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TROVA Tab. Bio-pharma</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 240.00 MRP 20mg x 10's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VASS Tab. Sandoz/Novartis</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 300.00 MRP 20mg x 10's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VASTIN Tab. Pharmadesh</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 20's pack: 160.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>XELPID Tab. Healthcare</h3>
    <p>Atorvastatin 10mg & 20mg/tablet (f.c) 10mg x 30's pack: 300.00 MRP 20mg x 10's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>XEROVA Tab. Beacon</h3>
    <p>Atorvastatin 10mg/tablet (f.c) 10mg x 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

      

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Fluvastatin" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Fluvastatin  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> FLUVASTATIN: Tablet  </h3>
          <p>  Ind: Primary hypercholesterolaemia & mixed dyslipidaemia (Fredrickson types IIa/IIb) as an adjunct to diet. To slow the progression of coronary atherosclerosis in patients with primary hypercholesterolae-mia, including mild forms, and coronary heart disease.<br><br>

C/I: Hypersensitivity to the drug. Active liver disease or unexplained, persistent elevations in serum transaminases. Pregnancy, lactation, women of childbearing potential unless they are taking adequate contraceptive precautions.<br><br>

A/R: Dyspepsia, nausea, abdominal pain & other minor gastrointestinal symptoms; insomnia, headache. Elevation of transaminase levels. Rare cases of hypersensitivity reactions, mainly rashes and urticaria, but very rarely also other skin reactions, thrombocytopenia, angioedema, vasculitis, and lupus erythematosus-like reactions have been reported.<br><br>

Precautions & Warnings: Caution is required in patients with a history of liver disease or heavy alcohol consumption, with unexplained diffuse myalgias, muscle tenderness or weakness, and marked elevation of creatine phosphokinase values, or with severe renal insufficiency.
Dosage: Prior to initiating fluvastatin, the patient should be placed on a standard cholesterol-lowering diet; dietary therapy should be continued during treatment. The recommended starting dose is 40mg (one 40mg capsule) once daily in the evening. In mild cases 20mg may be adequate. At very high cholesterol levels, the dosage may be increased to 80mg daily (one 40mg capsule twice daily or one 80mg XL tablet once daily in the evening). Interactions: Bile acid-sequestering agents; cimetidine, ranitidine, omeprazole; rifmapicin. Note: For further information, please see manufacturer's literature of full prescribing information.  </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>FLUVAS 20 Cap. Silva</h3>
    <p>Fluvastatin 20mg/capsule
20mg x 12's pack: 144.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LESCOL Cap. Novartis</h3>
    <p>Fluvastatin 20mg & 40mg/capsule 20mg x 28's pack: 700.00 MRP 40mg x 28's pack: 980.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LESCOL XL Tab. Novartis</h3>
    <p>Fluvastatin 80mg/tablet (prolonged release)
80mg x 28's pack: 1092.00 MRP</p>   
</div><!-- collapsible -->
              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Lovastatin" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Lovastatin   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> LOVASTATIN: Tablet  </h3>
          <p> Ind: Hypercholesterolaemia (lovastatin reduces both normal & elevated LDL cholesterol concentrations). To slow the progression of coronary atherosclerosis in patients with coronary heart disease.<br><br>
C/I: Active liver disease, unexplained transaminase elevations. Pregnancy & lactation. S/E: Chest pain, acid regurgitation, dry mouth, vomiting, arthralgia, insomnia, paresthesia, alopecia, pruritus & eye irritation.<br><br>
Caution: Alcoholics; past history of liver disease. Dose: Usual recommended starting dose is 20mg once a day given with the evening meal; (dose range may be 10mg to max. 80mg/day in single or 2 divided doses). In renal insufficiency (creatinine clearance < 30ml/min) dosage increase above 20mg/day should be carefully considered & if deemed necessary,
implemented cautiously.   </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOVATIN Tab. Ambee</h3>
    <p>Lovastatin 20mg/tablet
20mg x 30's pack: 303.30 MRP</p>   
</div><!-- collapsible -->
              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Rosuvastatin" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Rosuvastatin   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ROSUVASTATIN: Tablet  </h3>
          <p>  Rosuvastatin is a synthetic lipid-lowering agent. It is available as rosuvastatin INN 10mg film-coated tablet.<br><br>

<strong>Ind:</strong> Heterozygous hypercholesterolemia (familial. and nonfamilial), homozygous hypercholesterolemia (familial), mixed dyslipidemia (Fredrickson type IIa and IIb).<br><br>

<strong>C/I:</strong> Rosuvastatin is contraindicated in patients with a known hypersensitivity to any component of this product. Rosuvastatin is contraindicated in patients with active liver disease or with unexplained persistent elevations of serum transaminases.<br><br>

<strong>S/E:</strong> Rosuvastatin is generally well tolerated. The most frequent adverse events thought to be related to rosuvastatin were myalgia, constipation asthenia, abdominal pain, and nausea.<br><br>

<strong>Pregnancy & lactation:</strong> Rosuvastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking this drug, therapy should be discontinued immediately and the patient apprised of the potential hazard to the fetus. It is not known whether rosuvastatin is excreted in human milk.<br><br>

<strong>Dosage & admin:</strong> Heterozygous hypercholesterolemia (familial and nonfmailial) and mixed dyslipidemia (Fredrickson type IIa and IIb): The usual recommended starting dose of rosuvastatin is 10mg once daily. Initiation of therapy with 5mg once daily may be considered for patients requiring less aggressive LDL-C reductions or who have predisposing factors for myopathy. For patients with marked hypercholesterolemia (LDL-C >190mg/dI) and aggressive lipid targets, a 20mg starting dose may be considered. A 40mg dose of rosuvastatin should be reserved for those patients who have not achieved goal LDL-C at 20mg. After initiation and/or upon titration of rosuvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.<br><br>

Homozygous hypercholesterolemia (familial): The recommended starting dose of rosuvastatin is 20mg once daily. The maximum recommended daily dose is 40mg.
Rosuvastatin should be used in these patients as an adjunct to other lipid-lowering treatments (e.g LDL apheresis) or if such treatments are unavailable.
Dosage in patients with renal insufficiency: No modification of dosage is necessary for patients with mild to moderate renal insufficiency. For patients with severe renal impairment (CLcr < 30ml/min/1.73 m2) not on hemodialysis, dosing of rosuvastatin should be started at 5mg once daily and not to exceed 10mg once daily. Pediatric patients: The safety and effectiveness in pediatric patients have not been established.
  </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>CRESTON 10 Tab. SK+F</h3>
    <p>Rosuvastatin INN 10mg/tablet (f.c). 10mg x 10's pack: 450.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ROSUVA 10 Tab. Square</h3>
    <p>Rosuvastatin INN 10mg/tablet (f.c). 10mg x 10's pack: 450.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ROVAST Tab. Healthcare</h3>
    <p>Rosuvastatin INN 5mg & 10mg/tablet (f.c). 5mg x 10's pack: 250.00 MRP 10mg x 10's pack: 400.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AVASTIN Tab. Beximco</h3>
    <p>Simvastatin 10mg/tablet. 30's pack: 450.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NOVASTIN Tab. Drug Inter.</h3>
    <p>Simvastatin 10mg/tablet. 30's pack: 330.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SIMACOR Tab. Square</h3>
    <p>Simvastatin 10mg/tablet. 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SIMVATIN Tab. Acme</h3>
    <p>Simvastatin 10mg & 20mg/tablet.
10mg x 20's pack: 220.00 MRP 20mg x 10's pack: 180.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VASTOCOR Tab. Incepta</h3>
    <p>Simvastatin 10mg/tablet. 30's pack: 360.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ZOSTIN Tab. Renata</h3>
    <p>Simvastatin 10mg/tablet. 30's pack: 424.80 MRP</p>   
</div><!-- collapsible -->


              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="Simvastatin" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Simvastatin  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> SIMVASTATIN: Tablet  </h3>
          <p> 

<strong>Ind:</strong> Hypercholesterolaemia- patients with
primary hypercholesterolaemia, in home response to diet & other non-pharmacological measures has been inadequate.
Coronary heart disease- in patients with a plasma cholesterol level 5.5mmol/l or greater. Concomitant therapy with immunosupp-ressives. 

<strong>C/I:</strong> Hypersensitivity to this product; active liver disease or persistant elevation of serum transaminase; porphyria; pregnancy, lactation. Women of child bearing potential unless adequately protected by non-hormonal methods. 

<strong>S/E:</strong> Headache, fatigue, insomnia, nausea, constipation or diarrhoea, flatulence, dyspepisa, abdominal cramps, myalgia, myositis, myopathy; rhabdomyolysis (rare) with acute renal failure secondary to myoglobinuria; hepatitis, pancreatitis; rash, angioedema.

<strong>Caution:</strong> Monitor liver function before and during treament; minor asymptomatic transient rises in serum transaminase may occur soon after initiation of therapy with simvastatin which do not require the drug to be discontinued; if the transaminase levels rise to three times the upper limit of normal & are persistent, the drug should be discontinued. History of liver disease. High alcohol intake. Advise patients to report muscle pain. Discontinue treatment if markedly elevated CPK levels occur or if myopathy is diagnosed. 

<strong>D/I:</strong> digoxin, coumarin derivatives.

<strong>Dosage & admin:</strong> The patient should be placed on a standard cholesterol-lowering diet before receiving simvastatin and should continue on this diet during treatment with simvastatin. Hypercholesterolaemia- initially 10mg once daily at night; dose range 10-40mg/day. (A marked response to simvastatin is seen within two weeks and the maximum therapeutic response occurs within four to six weeks. The response is maintained during continuation of therapy. When therapy with simvastatin is stopped, total cholesterol has been shown to return to pretreatment levels.) Adjustment of dosage, if required, should be made at intervals of not less than four weeks, depending on the patient's individual response.
(If LDL-cholesterol level falls below 1.94
mmol/l or total serum cholesterol level falls below 3.6 mmol/l, consideration should be given to reduce the dose of simvastatin.) CHD- initially 20mg/day once daily at night. (Adjustment of dosage, if required, should be made as specified above for 'hypercholesterolaemia').
Concomitant therapy with immunosu- ppressives- maximum 10mg/day.   </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>INOSIT Tab. ACI</h3>
    <p>Inositol nicotinate BP 500mg & 750mg/tablet 500mg x 50's pack: 250.00 MRP
750mg x 50's pack: 375.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NICOSIT Tab. Incepta</h3>
    <p>Inositol nicotinate BP 500mg & 750mg/tablet 500mg x 20's pack: 100.00 MRP
750mg x 20's pack: 140.00 MRP</p>   
</div><!-- collapsible -->
              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Nicotinic acid group" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Nicotinic acid group   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> INOSITOL NICOTINATE: Tablet  </h3>
          <p>  Inositol nicotinate is the hexanicotinic acid ester of meso-inositol, also called inositol hexaniacinate (IHN) or inositol hexanicotinate or inositol nicotinate. The compound consists of six molecules of nicotinic acid and one molecule of inositol. It is available as inositol nicotinate BP 500mg and 750mg tablet.<br><br>

<strong>Mode of action:</strong> Pharmacokinetic studies have indicated that inositol nicotinate ester is absorbed intact and hydrolyzed in the body with release of free niacin and inositol. It has been proven effective at lowering VLDL, LDL and total cholesterol and triglyceride levels while raising HDL levels. Niacin is vital for cellular
metabolism. Due to its vasodilatory effects, niacin has been prescribed for the treatment of cardiovascular disease, particularly the hyperlipidemias.<br><br>

<strong>Ind:</strong> Inositol nicotinate has a fairly broad range of therapeutic applications. The most well researched conditions include the hyperlipidemias, Raynaud's disease and intermittent claudication. Promising applications, which bear further investigation, include its use for stasis ulcers, dysmenorrhea, dermatitis herpetiformis, alcoholism, diabetes, cancer prevention and hypertension.<br><br>

<strong>C/I:</strong> Inositol nicotinate is contraindicated to children, early stage of stroke & people who have recently had a heart attack. It should not be used if any one is allergic to one or any of its ingredients. S/E: The most common side effects are headache, rash, paraesthesia, dizziness, nausea and vomiting, flushing, excessive fluid retention in the body tissues, postural hypotension, fainting.<br><br>

<strong>Precautions:</strong> Cautions should be exercised in patients with angina not well controlled by medical treatment and decreased blood supply through the vessels of the brain (cerebrovascular insufficiency).<br><br>

<strong>Pregnancy & lactation:</strong> There is no information available about the safety of this medicine during pregnancy, therefore it is not recommended for use during pregnancy, unless considered essential by the physician.There is no information available regarding the safety of this medicine during breast-feeding.<br><br>

<strong>Dosage & admin:</strong> Recommended dosage for lipid-lowering and improving conditions related to peripheral vascular insufficiency ranges from 1500mg to 4 gms daily in 2 to 3 divided dosages.
Drug inter: There are no significant interactions reported with this medicine.  </p>
        </div><!-- collapsible -->



<div data-role="collapsible"> <!-- collapsible -->
    <h3>INOSIT Tab. ACI</h3>
    <p>Inositol nicotinate BP 500mg & 750mg/tablet 500mg x 50's pack: 250.00 MRP
750mg x 50's pack: 375.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NICOSIT Tab. Incepta</h3>
    <p>Inositol nicotinate BP 500mg & 750mg/tablet 500mg x 20's pack: 100.00 MRP
750mg x 20's pack: 140.00 MRP</p>   
</div><!-- collapsible -->

              

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



</body> 
</html> 
